[go: up one dir, main page]

WO2015100929A1 - Method for constructing eukaryotic gene knockout library by using crispr/cas9 system - Google Patents

Method for constructing eukaryotic gene knockout library by using crispr/cas9 system Download PDF

Info

Publication number
WO2015100929A1
WO2015100929A1 PCT/CN2014/078586 CN2014078586W WO2015100929A1 WO 2015100929 A1 WO2015100929 A1 WO 2015100929A1 CN 2014078586 W CN2014078586 W CN 2014078586W WO 2015100929 A1 WO2015100929 A1 WO 2015100929A1
Authority
WO
WIPO (PCT)
Prior art keywords
sgrna
library
cells
sequence
cas9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2014/078586
Other languages
French (fr)
Chinese (zh)
Inventor
魏文胜
周悦欣
朱诗优
蔡昌祖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peking University
Original Assignee
Peking University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peking University filed Critical Peking University
Publication of WO2015100929A1 publication Critical patent/WO2015100929A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids

Definitions

  • the present invention relates to the field of genomics and genetic engineering, and in particular to a method for constructing a eukaryotic gene knockout library using the CRISPR/Cas9 system. Background technique
  • Gene knockout a technical means of destroying or altering the function of a gene by destroying or altering its gene sequence.
  • Commonly used gene knockout methods include: zinc finger nucleases (ZFNs) (Miller et al., 2007; Porteus and Baltimore, 2003; Wood et al., 2011), transcription factor activating factor nucleases (TALEN) (Miller et Al., 2011; Wood et al., 2011; Zhang et al., 2011), and recently discovered the second class of adaptive immune system CRISPER/Cas9 systems for prokaryotes (Cong et al., 2013; Mali et al., 2013) and so on.
  • ZFNs zinc finger nucleases
  • TALEN transcription factor activating factor nucleases
  • the CRISPER/Cas9 system was originally used by the bacterial immune system to protect against foreign viruses or plasmids.
  • Cas9 endonuclease cleaves double-stranded DNA under the guidance of sgRNA, causing genomic double-strand breaks, resulting in repair errors (base deletion or insertion) using the instability of cellular genome repair. It may cause loss of gene function and achieve the purpose of gene knockout.
  • lentiviral vector-based RNA interference libraries Prior to the generation of knockout libraries, lentiviral vector-based RNA interference libraries became an effective tool for studying gene function. Due to their convenience, shRNA libraries have been widely used in recent years. These shRNA interference libraries are used to search for genes related to a specific function. The methods are summarized as follows: packaging viruses using a lentiviral packaging system; infecting target cells with viruses; using antibiotics or streams The cytometer enriches the cells infected and integrated with the virus, that is, the library cells; screens the cells having the function-related traits to be studied; extracts the genomic DNA of the selected cells and the untreated library cells; and amplifies the shRNA integration by PCR Sections or amplified shRNA library design barcodes, using deep sequencing technology for sequencing; matching the sequencing results with known shRNA; analyzing and calculating the degree of enrichment of different shRNAs, thereby further studying the highly enriched The function of the gene corresponding to shRNA.
  • the shRNA library is not a knockout library and can only partially silence gene expression.
  • some knockout libraries have been reported, particularly KBM7 cells, which are part of haploid cells, can be used to construct knockout libraries, but their stability and efficiency are problematic, and the system is limited to specific cell lines, The scope of application is limited. Summary of the invention The present invention aims to construct a eukaryotic gene knockout library, and a method for efficiently and rapidly identifying gene functions based on functional screening, and can achieve large-scale, high-throughput and coverage of whole genomes.
  • the present invention first provides a method for constructing a eukaryotic gene knockout library using the CRISPR/Ca S 9 system, comprising the steps of:
  • sgRNA action site 5'-G-Nx-NGG-3' design and synthesize sgRNA monomer targeting the above-mentioned site of action, designing for the same sgRNA action site
  • Two sgRNA monomers the sequence of which is forward monomer: 5'-ACCG-Nx-3', reverse monomer: 5'-AAAC-N' ⁇ -3', where N' X is the inverse of Nx
  • N and N' represent a base, T, G or C;
  • the PLL3.7 vector is ligated to replace the U6 promoter on the original vector, and the constructed vector and ii are obtained. Mix the mixture, add fisfil restriction endonuclease and T4 ligase, 37 ° C for 5 min, 16 C 5 min, repeat 10 cycles;
  • step 4 Inoculate the eukaryotic cell line constructed in step 1) with the harvested virus solution at 0.01 ⁇ MOI ⁇ 0.3. After the cells are cultured, the cells with green fluorescence are sorted by flow cytometry to obtain the eukaryotic gene. Knockout cell library.
  • the eukaryotic host cell in the step 1) includes, but is not limited to, HEK293T, HT1080, HeLa cells and the like.
  • the flexible Linker sequence described in step 1) is p2A:
  • the present invention also provides a library of eukaryotic gene knockout cells constructed by the above method.
  • the present invention further provides a method for studying gene function, extracting genomic DNA of a cell based on the eukaryotic gene knockout cell library, designing a primer, PCR-amplifying a DNA fragment containing the sgRNA sequence, and using deep sequencing technology (Deep Sequencing)
  • the amplified product was sequenced, the sequencing result was analyzed, and the function of the gene corresponding to the sgRNA was determined by comparing the degree of enrichment of the sgRNA.
  • the primer sequence is a forward primer: 5'-TATCTTGTGGAAAGGACGAAAC ACC-3 ', reverse primer: 5'-AATACGGTTATCCACGCGGC-3'.
  • the number of cycles of amplification is 25-30.
  • the method for constructing the eukaryotic gene knockout library provided by the present invention firstly expresses the gene encoding the Cas9 and OCT1 proteins in a eukaryotic cell line, selects a cell line stably expressing Cas9, and performs library construction and function screening. Its greatest advantage is that this method can be applied to most eukaryotic cell lines, independent of specific cell lines. In addition, the functional screening has a high positive rate and a low background value. The large-scale screening method greatly reduces the cost and overcomes the problem of high time and labor costs caused by single preparation of knockout cells. DRAWINGS
  • Figure 1 is a schematic view showing the structure of the Cas9 expression vector (a) and the sgRNA expression vector (b) of the present invention.
  • Figure 2 is a flow chart showing the implementation of a high-throughput method for constructing a eukaryotic gene knockout library using the CRISPR/Cas system and for gene function screening.
  • Fig. 3 shows that the system involved in the method of the present invention can effectively cause genomic repair errors in the three cell lines HEK293T, HT1080 and HeLa to achieve gene knockout.
  • Figure 4 is a ranking of candidate positive genes after screening using anthrax toxin chimeric toxin and diphtheria toxin, respectively, using the method of the present invention; wherein: a: heat map shows side sgRNA binding deep sequencing analysis of sputum toxin and diphtheria toxin host Summary of gene results; b and c: sgRNAs enriched after anthrax toxin and diphtheria toxin screening, and the genes they target. The degree of enrichment of sgRNA is obtained by dividing the normalized average experimental reading by the control value. The chart values represent the average of the three values, arranged from high to low. Red markers indicate sgRNAs as well as known toxin-associated host genes. d and e: The T7E1 digestion method indicates the insertion or deletion mutation rate (indels) of a specific DNA sequence caused by various sgRNAs of AN XR1(d) or HBEGF(e).
  • a heat map shows side sgRNA binding
  • Fig. 5 is a graph showing that the ANTXR1 gene which is most enriched after screening for anthrax toxin chimeric toxin in Example 1 of the present invention is highly resistant to anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.
  • Fig. 6 shows that the PECR gene of the anthrax toxin chimeric toxin in the first embodiment of the present invention has a certain resistance to the anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.
  • Figure 7 is a graph showing that the HBEGF gene which is most enriched after screening for diphtheria toxin in Example 2 of the present invention is highly resistant to diphtheria toxin and is not resistant to anthrax toxin chimeric toxin.
  • Figure 8 is a schematic view showing the structure of the vector pOCTl-2A-Cas9-IRES-BSD in the present invention. detailed description
  • Example 1 Construction of a CRISPR/Cas9 knockout library and screening for genes associated with anthrax toxin cytotoxicity
  • 293T cells were plated at a density of 3 ⁇ 10 6 in four 10 cm diameter cell culture plates, and the library plasmid and the other two viral packaging plasmids psPAX2 and PMD2.G were transferred into the cells using polyethylenimine (PEI). After 70 hours, the virus solution was harvested;
  • PEI polyethylenimine
  • the selected cells were plated at a density of 1 ⁇ 10 6 in 10 10 cm cell culture plates, and three groups of parallel experiments were performed.
  • the PA protein was 70 ng/mL and the LFn-DTA protein was 50 ng/mL. After culturing for 48 hours, replace the fresh medium and repeat the process three times;
  • genomic DNA DN A of the surviving cells and the other three groups of untreated library cells were extracted, and the above primers were used for PCR amplification.
  • the total amount of genomic DNA of each group as a template was 8 ⁇ ⁇ , PCR was performed for 26 cycles, and PCR was performed. product;
  • the purified PCR products were sequenced using HiSeq2500 and ranked according to the abundance changes of sgRNA before and after toxin treatment, and the top three were all known receptors for anthrax toxin. And to find a new gene PECR that may be related to the toxicity of anthrax toxin.
  • Example 2 Construction of a CRISPR/Cas9 knockout library and screening for genes associated with diphtheria toxin cytotoxicity
  • 293T cells were plated at a density of 3 ⁇ 10 6 in four 10 cm diameter cell culture plates, and the library plasmid and the other two viral packaging plasmids psPAX2 and PMD2.G were transferred into the cells using polyethylenimine (PEI). After 70 hours, the virus solution was harvested;
  • PEI polyethylenimine
  • the selected cells were plated at a density of 1 ⁇ 10 6 in 10 10 cm cell culture plates, and three groups of parallel experiments were performed. DT protein 7.5 ng/mL was added to the culture medium, cultured for 48 hours, and the fresh culture solution was replaced. Repeat this process three times; 7. Extract genomic DNA and amplify
  • genomic DNA DN A of the surviving cells and the other three groups of untreated library cells were extracted, and the above primers were used for PCR amplification.
  • the total amount of genomic DNA of each group as a template was 8 ⁇ ⁇ , PCR was performed for 26 cycles, and PCR was performed. product;
  • the purified PCR product was sequenced using HiSeq 2500 and sorted according to the abundance change of sgRNA before and after toxin treatment, and the first place was the known receptor for diphtheria toxin.
  • Figure 1 is a schematic view showing the structure of the Cas9 expression vector (a) and the sgRNA expression vector (b) of the present invention.
  • Figure 2 is a flow chart showing the implementation of a high-throughput method for constructing a eukaryotic gene knockout library using the CRISPR/Cas system and for gene function screening.
  • Fig. 3 shows that the system involved in the coding method can effectively cause genomic repair errors in the three cell lines HEK293T, HT1080 and HeLa to achieve gene knockout.
  • Fig. 4 is a result of sorting candidate positive genes after screening using anthrax toxin chimeric toxin and diphtheria toxin, respectively, using the method of the present invention.
  • Fig. 5 is a graph showing that the ANTXR1 gene which is most enriched after screening for anthrax toxin chimeric toxin in Example 1 of the present invention has strong resistance to anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.
  • Fig. 6 is a diagram showing that the PECR gene in the candidate gene after screening for anthrax toxin chimeric toxin in Example 1 of the present invention has certain resistance to anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.
  • Fig. 7 shows that the HBEGF gene which is most enriched after screening for diphtheria toxin in Example 2 of the present invention is highly resistant to diphtheria toxin and is not resistant to anthrax toxin chimeric toxin.
  • the present invention provides a method for constructing a eukaryotic gene knockout library using the CRISPR/Cas9 system, and the greatest advantage of the method is that the method can be applied to most eukaryotic cell lines without being affected by a specific cell line. limit.
  • the functional screening has a high positive rate and a low background value.
  • the large-scale screening method greatly reduces the cost and overcomes the problem of high time and labor cost caused by single preparation of knockout cells. references

Landscapes

  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Provided in the present invention is a method for constructing a eukaryotic gene knockout library by using a CRISPR/Cas9 system. The method comprises the following steps: first expressing genes encoding Cas9 and Oct1 proteins into a eukaryotic cell line; screening to obtain a cell line which stably expresses Cas9; and then carrying out library construction and functional screening once again.

Description

利用 CRISPR/Cas9系统构建真核基因敲除文库的方法 技术领域  Method for constructing eukaryotic gene knockout library using CRISPR/Cas9 system

本发明涉及基因体学及基因工程领域, 具体地说, 涉及一种利用 CRISPR/Cas9系统构建真核基因敲除文库的方法。 背景技术  The present invention relates to the field of genomics and genetic engineering, and in particular to a method for constructing a eukaryotic gene knockout library using the CRISPR/Cas9 system. Background technique

基因敲除, 即针对某个特定的基因, 通过破坏或改变其基因序列令其功能 丧失的一种技术手段。 常用的基因敲除方法包括: 锌指核酸酶(ZFNs ) (Miller et al., 2007; Porteus and Baltimore, 2003; Wood et al., 2011)、 类转录因子活化因子核 酸酶 ( TALEN ) (Miller et al., 2011; Wood et al., 2011; Zhang et al., 2011), 以及最 近发现的原核生物第二类适应性免疫系统 CRISPER/Cas9系统 (Cong et al., 2013; Mali et al., 2013)等。 CRISPER/Cas9系统原本被细菌免疫系统用来抵御外源病毒 或质粒。在第二类 CRISPER系统中, Cas9核酸内切酶在 sgRNA的引导下切割双链 DNA, 造成基因组双链断裂, 利用细胞基因组修复的不稳定性产生修复错误(碱 基的缺失或插入), 从而可能造成基因功能的丧失, 实现基因敲除的目的。  Gene knockout, a technical means of destroying or altering the function of a gene by destroying or altering its gene sequence. Commonly used gene knockout methods include: zinc finger nucleases (ZFNs) (Miller et al., 2007; Porteus and Baltimore, 2003; Wood et al., 2011), transcription factor activating factor nucleases (TALEN) (Miller et Al., 2011; Wood et al., 2011; Zhang et al., 2011), and recently discovered the second class of adaptive immune system CRISPER/Cas9 systems for prokaryotes (Cong et al., 2013; Mali et al., 2013) and so on. The CRISPER/Cas9 system was originally used by the bacterial immune system to protect against foreign viruses or plasmids. In the second type of CRISPR system, Cas9 endonuclease cleaves double-stranded DNA under the guidance of sgRNA, causing genomic double-strand breaks, resulting in repair errors (base deletion or insertion) using the instability of cellular genome repair. It may cause loss of gene function and achieve the purpose of gene knockout.

在基因敲除文库产生之前, 基于慢病毒载体的 RNA干扰文库成为研究基因 功能的有效工具。 由于其便利性, 近年来 shRNA文库得以普遍应用, 利用这类 shRNA干扰文库寻找与某特定功能相关的基因, 方法概括如下: 使用慢病毒包装 系统包装病毒; 使用病毒感染靶细胞; 利用抗生素或流式细胞仪富集病毒感染并 整合的细胞, 即为文库细胞; 筛选具有待研究功能相关性状的细胞; 提取筛选出 的细胞和未作处理的文库细胞的基因组 DNA;通过 PCR扩增 shRNA整合的区段或 扩增 shRNA文库设计时自带的条码(barcodes ), 利用深度测序技术进行测序; 将 测序结果与已知 shRNA进行匹配; 分析计算不同 shRNA的富集程度, 从而进一步 研究被高度富集的 shRNA所对应基因的功能。  Prior to the generation of knockout libraries, lentiviral vector-based RNA interference libraries became an effective tool for studying gene function. Due to their convenience, shRNA libraries have been widely used in recent years. These shRNA interference libraries are used to search for genes related to a specific function. The methods are summarized as follows: packaging viruses using a lentiviral packaging system; infecting target cells with viruses; using antibiotics or streams The cytometer enriches the cells infected and integrated with the virus, that is, the library cells; screens the cells having the function-related traits to be studied; extracts the genomic DNA of the selected cells and the untreated library cells; and amplifies the shRNA integration by PCR Sections or amplified shRNA library design barcodes, using deep sequencing technology for sequencing; matching the sequencing results with known shRNA; analyzing and calculating the degree of enrichment of different shRNAs, thereby further studying the highly enriched The function of the gene corresponding to shRNA.

然而, shRNA文库并不是基因敲除文库, 只能部分沉默基因表达。 存在许 多不足, 例如对特定基因表达的影响往往不能导致表型的改变; 可能错误地抑制 不相关基因表达等。 虽然有一些基因敲除文库已被报道, 特别是 KBM7细胞, 它 是部分单倍体细胞, 可用于构建敲除文库, 但其稳定性和效率都存在问题, 而且 该系统局限于特定细胞系, 应用范围受限。 发明内容 本发明旨在构建真核基因敲除文库, 以及基于功能性筛选高效快速鉴定基 因功能的方法学, 并能够达到大规模、 高通量及覆盖全基因组的目的。 However, the shRNA library is not a knockout library and can only partially silence gene expression. There are many deficiencies, such as the influence of specific gene expression often does not lead to phenotypic changes; may incorrectly inhibit irrelevant gene expression and the like. Although some knockout libraries have been reported, particularly KBM7 cells, which are part of haploid cells, can be used to construct knockout libraries, but their stability and efficiency are problematic, and the system is limited to specific cell lines, The scope of application is limited. Summary of the invention The present invention aims to construct a eukaryotic gene knockout library, and a method for efficiently and rapidly identifying gene functions based on functional screening, and can achieve large-scale, high-throughput and coverage of whole genomes.

为了实现本发明目的,本发明首先提供一种利用 CRISPR/CaS9系统构建真核 基因敲除文库的方法, 包括以下步骤: In order to achieve the object of the present invention, the present invention first provides a method for constructing a eukaryotic gene knockout library using the CRISPR/Ca S 9 system, comprising the steps of:

1 )构建稳定表达 OCT1蛋白和 Cas9蛋白的真核细胞系: 将编码蛋白 OCT1和 Cas9的 DNA序列 通过柔性 Linker连接 , 然后 克隆至慢病毒载体 pOCTl-2A-Cas9-IRES-BSD ( SEQ ID No. l , 图 8 ) 上; 用构建好的载体转染真核 宿主细胞; 筛选稳定表达 OCT 1蛋白和 Cas9蛋白的真核细胞系;  1) Construction of a eukaryotic cell line stably expressing OCT1 protein and Cas9 protein: The DNA sequences encoding the proteins OCT1 and Cas9 were ligated via a flexible Linker, and then cloned into the lentiviral vector pOCTl-2A-Cas9-IRES-BSD (SEQ ID No.). l, Figure 8); transfecting eukaryotic host cells with the constructed vector; screening for eukaryotic cell lines stably expressing OCT 1 protein and Cas9 protein;

2 ) sgRNA质粒文库的构建:  2) Construction of sgRNA plasmid library:

i. 根据 sgRNA作用位点的 DNA序列 5' -G-Nx-NGG-3' , 其中 19 < x < 22, 设 计并合成针对上述作用位点的 sgRNA单体,针对同一个 sgRNA作用位点设计两个 sgRNA单体,其序列分别为正向单体: 5' -ACCG-Nx-3' ,反向单体: 5' -AAAC-N' χ-3' , 其中 N' X为 Nx的反向互补序列, N和 N' 表示碱基 、 T、 G或 C;  i. According to the DNA sequence of sgRNA action site 5'-G-Nx-NGG-3', where 19 < x < 22, design and synthesize sgRNA monomer targeting the above-mentioned site of action, designing for the same sgRNA action site Two sgRNA monomers, the sequence of which is forward monomer: 5'-ACCG-Nx-3', reverse monomer: 5'-AAAC-N' χ-3', where N' X is the inverse of Nx To a complementary sequence, N and N' represent a base, T, G or C;

ii. 将上述合成的针对同一个 sgRNA作用位点的两个 sgRNA单体退火形成 具有粘性末端的双链 DNA, 并将针对所有基因合成的 sgRNA单体经退火形成的 双链 DNA等量混合;  Ii. annealing the two sgRNA monomers synthesized above for the same sgRNA action site to form double-stranded DNA having sticky ends, and mixing the double-stranded DNA formed by annealing the sgRNA monomers synthesized for all genes in equal amounts;

iii. 将人 U6启动子连接 ccdB序列以及序列 5' -G-Nx-NGG-3'之后,连入 PLL3.7 载体中替换原载体上的 U6启动子, 将构建好的载体与 ii中得到的混合物混合, 加入 fismfil限制性内切酶和 T4连接酶, 37°C 5 min, 16 C 5 min, 重复 10个循环;  Iii. After the human U6 promoter is ligated to the ccdB sequence and the sequence 5'-G-Nx-NGG-3', the PLL3.7 vector is ligated to replace the U6 promoter on the original vector, and the constructed vector and ii are obtained. Mix the mixture, add fisfil restriction endonuclease and T4 ligase, 37 ° C for 5 min, 16 C 5 min, repeat 10 cycles;

iv. 将上述产物转化至 Transl-Tl感受态细胞中, 提取质粒, 即构建得到 sgRNA质粒文库;  Iv. transforming the above product into Transl-Tl competent cells, extracting the plasmid, and constructing the sgRNA plasmid library;

3 )将上述质粒与质粒 psPAX2和 PMD2.G共转染至 HEK293T细胞中, 培养细 胞, 收获病毒液;  3) co-transfecting the above plasmid with the plasmids psPAX2 and PMD2.G into HEK293T cells, culturing the cells, and harvesting the virus solution;

4 )用收获的病毒液按 0.01≤MOI≤ 0.3接种步骤 1 )中构建得到的真核细胞系, 细 胞经培养后, 使用流式细胞仪分选带有绿色荧光的细胞, 即获得真核基因敲除的细胞 文库。  4) Inoculate the eukaryotic cell line constructed in step 1) with the harvested virus solution at 0.01 ≤ MOI ≤ 0.3. After the cells are cultured, the cells with green fluorescence are sorted by flow cytometry to obtain the eukaryotic gene. Knockout cell library.

前述的方法,步骤 1 )中所述真核宿主细胞包括但不限于 HEK293T、HT1080、 HeLa细胞等。  The aforementioned method, the eukaryotic host cell in the step 1) includes, but is not limited to, HEK293T, HT1080, HeLa cells and the like.

前 述 的 方 法 , 步 骤 1 ) 中 所 述 柔 性 Linker序 列 为 p2A :  In the method described above, the flexible Linker sequence described in step 1) is p2A:

GAGGAGAACCCTGGACCT-3 '。 本发明还提供由上述方法构建的真核基因敲除细胞文库。 GAGGAGAACCCTGGACCT-3 '. The present invention also provides a library of eukaryotic gene knockout cells constructed by the above method.

本发明进一步提供一种研究基因功能的方法, 基于所述真核基因敲除细胞 文库, 提取细胞的基因组 DNA, 设计引物, PCR扩增含有 sgRNA序列的 DNA片 段,利用深度测序技术(Deep Sequencing )对扩增产物进行测序,分析测序结果, 通过比较 sgRNA的富集程度, 来确定 sgRNA所对应基因的功能。  The present invention further provides a method for studying gene function, extracting genomic DNA of a cell based on the eukaryotic gene knockout cell library, designing a primer, PCR-amplifying a DNA fragment containing the sgRNA sequence, and using deep sequencing technology (Deep Sequencing) The amplified product was sequenced, the sequencing result was analyzed, and the function of the gene corresponding to the sgRNA was determined by comparing the degree of enrichment of the sgRNA.

其中,引物序列为正向引物: 5' -TATCTTGTGGAAAGGACGAAAC ACC-3 ' , 反向引物: 5' -AATACGGTTATCCACGCGGC-3'。 扩增的循环数为 25-30个。  Among them, the primer sequence is a forward primer: 5'-TATCTTGTGGAAAGGACGAAAC ACC-3 ', reverse primer: 5'-AATACGGTTATCCACGCGGC-3'. The number of cycles of amplification is 25-30.

本发明提供的真核基因敲除文库的构建方法, 先将编码 Cas9和 OCT1蛋白的基 因表达于真核细胞系中, 筛选获得稳定表达 Cas9的细胞系, 再进行文库构建和功能 筛选。 其最大的优点在于: 可将此方法应用于绝大多数真核细胞系中, 不受特定细 胞系的限制。 另外, 进行功能性筛选阳性率高, 背景值低。 大规模的筛选方法极大 降低了成本, 克服了单个制备基因敲除细胞, 所导致的时间和劳动成本高的问题。 附图说明  The method for constructing the eukaryotic gene knockout library provided by the present invention firstly expresses the gene encoding the Cas9 and OCT1 proteins in a eukaryotic cell line, selects a cell line stably expressing Cas9, and performs library construction and function screening. Its greatest advantage is that this method can be applied to most eukaryotic cell lines, independent of specific cell lines. In addition, the functional screening has a high positive rate and a low background value. The large-scale screening method greatly reduces the cost and overcomes the problem of high time and labor costs caused by single preparation of knockout cells. DRAWINGS

图 1为本发明 Cas9表达载体(a )和 sgRNA表达载体(b ) 的结构示意图。 图 2为本发明利用 CRISPR/Cas系统构建真核基因敲除文库, 并用于基因功 能筛选的高通量方法学的实施流程图。  Figure 1 is a schematic view showing the structure of the Cas9 expression vector (a) and the sgRNA expression vector (b) of the present invention. Figure 2 is a flow chart showing the implementation of a high-throughput method for constructing a eukaryotic gene knockout library using the CRISPR/Cas system and for gene function screening.

图 3为本发明方法所涉及的系统在 HEK293T、 HT1080、 HeLa三个细胞系 中均可有效的造成基因组修复错误以达到基因敲除目的。  Fig. 3 shows that the system involved in the method of the present invention can effectively cause genomic repair errors in the three cell lines HEK293T, HT1080 and HeLa to achieve gene knockout.

图 4为应用本发明所述方法分别使用炭疽毒素嵌合毒素和白喉毒素进行筛选后的候 选阳性基因排序结果; 其中, a: 热图显示侧 sgRNA 结合深度测序分析筛 疽 毒素及白喉毒素宿主相关基因的结果汇总; b和 c: 分别为炭疽毒素和白喉毒素筛选后所 富集的 sgRNAs以及它们所针对的基因。 sgRNA的富集程度是通过计算标准化的平均实 验读值除以对照值得到。 图表数值表示三个值的平均值, 按照从高到低排列。 红色标记 表示 sgRNAs以及已知的毒素相关宿主基因。 d和 e: T7E1酶切法表示针对 AN XRl(d) 或 HBEGF(e)的各种不同 sgRNAs所造成的特定 DNA序列的插入或缺失突变率( indels )。  Figure 4 is a ranking of candidate positive genes after screening using anthrax toxin chimeric toxin and diphtheria toxin, respectively, using the method of the present invention; wherein: a: heat map shows side sgRNA binding deep sequencing analysis of sputum toxin and diphtheria toxin host Summary of gene results; b and c: sgRNAs enriched after anthrax toxin and diphtheria toxin screening, and the genes they target. The degree of enrichment of sgRNA is obtained by dividing the normalized average experimental reading by the control value. The chart values represent the average of the three values, arranged from high to low. Red markers indicate sgRNAs as well as known toxin-associated host genes. d and e: The T7E1 digestion method indicates the insertion or deletion mutation rate (indels) of a specific DNA sequence caused by various sgRNAs of AN XR1(d) or HBEGF(e).

图 5为本发明实施例 1 中炭疽毒素嵌合毒素筛选后被最大富集的 ANTXR1 基因对于炭疽毒素嵌合毒素具有较强抗性, 对白喉毒素不具有抗性。  Fig. 5 is a graph showing that the ANTXR1 gene which is most enriched after screening for anthrax toxin chimeric toxin in Example 1 of the present invention is highly resistant to anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.

图 6为本发明实施例 1中炭疽毒素嵌合毒素筛选后候选基因中 PECR基因对 于炭疽毒素嵌合毒素具有一定的抗性, 对白喉毒素不具有抗性。  Fig. 6 shows that the PECR gene of the anthrax toxin chimeric toxin in the first embodiment of the present invention has a certain resistance to the anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.

图 7为本发明实施例 2中白喉毒素筛选后被最大富集的 HBEGF基因对于白 喉毒素具有较强抗性, 对炭疽毒素嵌合毒素不具有抗性。 图 8为本发明中载体 pOCTl-2A-Cas9-IRES-BSD的结构示意图。 具体实施方式 Figure 7 is a graph showing that the HBEGF gene which is most enriched after screening for diphtheria toxin in Example 2 of the present invention is highly resistant to diphtheria toxin and is not resistant to anthrax toxin chimeric toxin. Figure 8 is a schematic view showing the structure of the vector pOCTl-2A-Cas9-IRES-BSD in the present invention. detailed description

以下实施例用于说明本发明, 但不用来限制本发明的范围。 若未特别指明, 实施 例均按照常规实验条件, 如 Sambrook等分子克隆实验手册( Sambrook J & Russell DW, Molecular cloning: a laboratory manual, 2001 ), 或按照制造厂商说明书建议的条件。 实施例 1 构建 CRISPER/Cas9基因敲除文库并筛选与炭疽毒素(anthrax toxin ) 细胞毒性相关的基因  The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention. Unless otherwise specified, the examples are based on routine experimental conditions, such as the Sambrook J & Russell DW, Molecular cloning: a laboratory manual, 2001, or as suggested by the manufacturer's instructions. Example 1 Construction of a CRISPR/Cas9 knockout library and screening for genes associated with anthrax toxin cytotoxicity

1. 文库 sgRNA的设计  1. Library Design of sgRNA

针对 296个基因, 每个基因找到 2-3个 sgRNA靶位点, 详见表 1。  For 296 genes, 2-3 sgRNA target sites were found for each gene, as shown in Table 1.

表 1 sgRNA文库的基因组成、 sgRNA靶位区域及用于构建 sgRNA质粒的引物序列 Table 1 Gene composition of sgRNA library, sgRNA target region and primer sequences for constructing sgRNA plasmid

Figure imgf000005_0001
/:/:/ O 98s8/-0H0si>l£ 6S0SSSZAV
Figure imgf000005_0001
/:/:/ O 98s8/-0H0si>l£ 6S0SSSZAV

Figure imgf000006_0001
Figure imgf000006_0001

9 9

Figure imgf000007_0001
Figure imgf000007_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV L 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV L

Figure imgf000008_0001
Figure imgf000008_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV

ν αιαιιαι νθΓΐ ν αιαιιαι νθΓΐ

。。 。 。 。 。 . . . . . .

98S8L0/PWZSlD/lDd 6Z600l/ST0Z OAV 6 98S8L0/PWZSlD/lDd 6Z600l/ST0Z OAV 6

Figure imgf000010_0001
S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV οτ
Figure imgf000010_0001
S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV Οτ

Figure imgf000011_0001
Figure imgf000011_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV ττ 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV Ττ

Figure imgf000012_0001
Figure imgf000012_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 飞 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV fly

 fly

 fly

fly

工:) 飞 Worker :) fly

 fly

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV

Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
9T 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
9T

Figure imgf000017_0001
Figure imgf000017_0001

98S8L0/PWZSlD/lDd 6Z600l/ST0Z OAV LI 98S8L0/PWZSlD/lDd 6Z600l/ST0Z OAV LI

Figure imgf000018_0001
Figure imgf000018_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 81 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 81

Figure imgf000019_0001
Figure imgf000019_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 61 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 61

Figure imgf000020_0001
Figure imgf000020_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV oz 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV Oz

Figure imgf000021_0001
Figure imgf000021_0001

98S8L0/PWZSlD/lDd 6Z600l/ST0Z OAV 98S8L0/PWZSlD/lDd 6Z600l/ST0Z OAV

Figure imgf000022_0001
Figure imgf000022_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV zz 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV Zz

Figure imgf000023_0001
Figure imgf000023_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV ίΖ 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV Ζ

Figure imgf000024_0001
Figure imgf000024_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV

Figure imgf000025_0001
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV
Figure imgf000025_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV

Figure imgf000026_0001
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV
Figure imgf000026_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 91 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 91

Figure imgf000027_0001
Figure imgf000027_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV LZ 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV LZ

Figure imgf000028_0001
Figure imgf000028_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 21 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV twenty one

Figure imgf000029_0001
S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 61
Figure imgf000029_0001
S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 61

Figure imgf000030_0001
Figure imgf000030_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV οε 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV Εε

Figure imgf000031_0001
Figure imgf000031_0001

98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV

Figure imgf000032_0001
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV
Figure imgf000032_0001

2. 高表达 Cas9的 HeLa细胞的筛选  2. Screening of HeLa cells with high expression of Cas9

( 1 ) 将 OCT1和 Cas9的 DNA序列通过 2A连接并通过 Gibson克隆方法装载到 慢病毒载体 pLenti-CMV-MCSSV-Bsd上;  (1) The DNA sequences of OCT1 and Cas9 were ligated through 2A and loaded into the lentiviral vector pLenti-CMV-MCSSV-Bsd by Gibson cloning method;

(2)将上述载体通过包装慢病毒感染的方法转入目标细胞;  (2) transferring the above vector into a target cell by a method of packaging a lentivirus infection;

(3 )在上述细胞的培养液中加入杀稻瘟菌素 (blasticidin)进行筛选, 并挑 取稳定表达 Cas9的单克隆;  (3) adding blasticidin to the culture medium of the above cells for screening, and picking up a single clone stably expressing Cas9;

3. 文库质粒的构建  3. Construction of library plasmid

(4) 寻找 sgRNA作用位点, 序列为 5' -G-Nx-NGG-3' , 其中 19<x<22; (4) Find the sgRNA action site, the sequence is 5'-G-Nx-NGG-3', where 19<x<22;

( 5 )合成针对上述作用位点的 sgRNA单体, 针对每一个位点, 其序列为, 正向: 5' -ACCG-Nx-3' , 反向: 5' -AAAC-N' χ-3' , 其中 N' x为 Nx的反向互 补配对序列; (5) synthesizing sgRNA monomers targeting the above-mentioned action sites, for each site, the sequence is, forward: 5'-ACCG-Nx-3', reverse: 5'-AAAC-N' χ-3 ' , where N' x is the reverse complementary pairing sequence of Nx;

(6) sgRNA载体的构建, 将人的 U6启动子连接 ccdB以及 gRNA结构, 用酶 Xba 1和 X/w 1连入 PLL3.7载体中替换原载体上的 U6启动子;  (6) Construction of sgRNA vector, human U6 promoter is ligated to ccdB and gRNA structure, and enzymes Xba 1 and X/w 1 are ligated into PLL3.7 vector to replace U6 promoter on original vector;

(7)将上述合成的针对同一个 sgRNA位点的两个单体, 用 TE缓冲液稀释到 ΙΟ μΜ,各取 22.5μ1,加入 5μ1 Taq Hifi Buffer,加热至 95 °C ,然后自然冷却至室温;(7) Diluting the two monomers synthesized above for the same sgRNA site with TE buffer to ΙΟ μΜ, each take 22.5μ1, add 5μ1 Taq Hifi Buffer, heat to 95 °C, then naturally cool to room temperature;

( 8 ) 上述针对所有基因 sgRNA的产物等量混合; (8) The above-mentioned products for all gene sgRNAs are mixed in equal amounts;

( 9 )上述混合物与 (6 ) 中构建的载体混合, 加入 mSI限制性内切酶和 T4 连接酶, 37°C 5 min, 16°C 5 min, 重复 10个循环;  (9) The above mixture is mixed with the vector constructed in (6), and mSI restriction enzyme and T4 ligase are added, and the mixture is repeated at 37 ° C for 5 min, 16 ° C for 5 min, and repeated for 10 cycles;

( 10 ) 上述产物转化至 Transl-Tl感受态细胞中;  (10) the above product is transformed into Transl-Tl competent cells;

( 11 )从上述转化产物中提取质粒, 构建文库质粒;  (11) extracting a plasmid from the above transformation product to construct a library plasmid;

4. 文库病毒的包装  4. Packaging of library viruses

将 293T细胞以 3 X 106的密度平铺于 4个 10cm直径的细胞培养板中, 使用聚氮 丙啶 (PEI )将文库质粒和其它两种病毒包装质粒 psPAX2和 PMD2.G转入细胞, 70小时后, 收获病毒液; 293T cells were plated at a density of 3×10 6 in four 10 cm diameter cell culture plates, and the library plasmid and the other two viral packaging plasmids psPAX2 and PMD2.G were transferred into the cells using polyethylenimine (PEI). After 70 hours, the virus solution was harvested;

5. 文库细胞的构建  5. Construction of library cells

将筛选出的表达 Cas9的 HeLa细胞以 4 χ 106的密度平铺于 10个 15cm直径的细 胞培养板中, 用上述病毒液按 MOI = 0.05进行感染, 感染 48小时后, 使用流式细 胞仪筛选出表达绿色荧光的细胞; The selected Cas9-expressing HeLa cells were plated at a density of 4 χ 10 6 in 10 15 cm-diameter cell culture plates, infected with the above virus solution at MOI = 0.05, and 48 hours after infection, using a flow cytometer. Screening for cells expressing green fluorescence;

6. 使用炭疽毒素进行筛选  6. Screening with anthrax toxin

将筛选出的细胞以 1 X 106的密度平铺于 10个 10cm的细胞培养板,共三组平行 实验, 在培养液中加入 PA蛋白 70 ng/mL, LFn-DTA蛋白 50 ng/mL, 培养 48小时, 更换新鲜培养液, 重复此过程三次; The selected cells were plated at a density of 1×10 6 in 10 10 cm cell culture plates, and three groups of parallel experiments were performed. The PA protein was 70 ng/mL and the LFn-DTA protein was 50 ng/mL. After culturing for 48 hours, replace the fresh medium and repeat the process three times;

7. 提取基因组 DNA并扩增  7. Extract genomic DNA and amplify

提取存活的细胞和另外三组未作任何处理的文库细胞的基因组 DN A , 使用 上述引物进行 PCR扩增, 每组作为模板的基因组 DNA总量为 8 μ§, PCR进行 26个 循环, 纯化 PCR产物; The genomic DNA DN A of the surviving cells and the other three groups of untreated library cells were extracted, and the above primers were used for PCR amplification. The total amount of genomic DNA of each group as a template was 8 μ § , PCR was performed for 26 cycles, and PCR was performed. product;

8. 测序并分析  8. Sequencing and analysis

纯化后的 PCR产物使用 HiSeq2500进行测序, 并根据 sgRNA在毒素处理前后 的丰度变化进行排序, 排在前三位的均为已知的炭疽毒素的受体。 并寻找到一个 新的可能与炭疽毒素毒性作用有关的基因 PECR。  The purified PCR products were sequenced using HiSeq2500 and ranked according to the abundance changes of sgRNA before and after toxin treatment, and the top three were all known receptors for anthrax toxin. And to find a new gene PECR that may be related to the toxicity of anthrax toxin.

实施例 2 构建 CRISPER/Cas9基因敲除文库并筛选与白喉毒素 (diphtheria toxin )细胞毒性相关的基因 Example 2 Construction of a CRISPR/Cas9 knockout library and screening for genes associated with diphtheria toxin cytotoxicity

1. 文库 sgRNA的设计  1. Library Design of sgRNA

针对 296个基因, 每个基因找到 2-3个 sgRNA靶位点, 详见表 1。  For 296 genes, 2-3 sgRNA target sites were found for each gene, as shown in Table 1.

2. 高表达 Cas9的 HeLa细胞的筛选 ( 1 ) 将 OCT1和 Cas9的 DNA序列通过 2A连接并通过 Gibson克隆方法装载到 慢病毒载体 pLenti-CMV-MCSSV-Bsd上; 2. Screening of HeLa cells with high expression of Cas9 (1) The DNA sequences of OCT1 and Cas9 were ligated by 2A and loaded into the lentiviral vector pLenti-CMV-MCSSV-Bsd by Gibson cloning method;

(2)将上述载体通过包装慢病毒感染的方法转入目标细胞;  (2) transferring the above vector into a target cell by a method of packaging a lentivirus infection;

(3 )在上述细胞的培养液中加入杀稻瘟菌素 ( blasticidin )进行筛选, 并挑 取稳定表达 Cas9的单克隆;  (3) adding blasticidin to the culture medium of the above cells for screening, and picking up a single clone stably expressing Cas9;

3. 文库质粒的构建  3. Construction of library plasmid

(4) 寻找 sgRNA作用位点, 序列为 5' -G-Nx-NGG-3' , 其中 19<x<22; (4) Find the sgRNA action site, the sequence is 5'-G-Nx-NGG-3', where 19<x<22;

( 5 )合成针对上述作用位点的 sgRNA单体, 针对每一个位点, 其序列为, 正向: 5' -ACCG-Nx-3' , 反向: 5' -AAAC-N' χ-3' , 其中 N' x为 Nx的反向互 补配对序列; (5) synthesizing sgRNA monomers targeting the above-mentioned action sites, for each site, the sequence is, forward: 5'-ACCG-Nx-3', reverse: 5'-AAAC-N' χ-3 ' , where N' x is the reverse complementary pairing sequence of Nx;

(6) sgRNA载体的构建, 将人的 U6启动子连接 ccdB以及 gRNA结构, 用酶 Xba 1和 X/w 1连入 PLL3.7载体中替换原载体上的 U6启动子;  (6) Construction of sgRNA vector, human U6 promoter is ligated to ccdB and gRNA structure, and enzymes Xba 1 and X/w 1 are ligated into PLL3.7 vector to replace U6 promoter on original vector;

(7)将上述合成的针对同一个 sgRNA位点的两个单体, 用 TE缓冲液稀释到 ΙΟμΜ, 各取 22.5μ1, 加入 5μ1 Taq Hifi Buffer, 加热至 95°C, 然后自然冷却至室温; (7) The above two monomers synthesized for the same sgRNA site were diluted to ΙΟμΜ with TE buffer, each taken 22.5 μl, added with 5 μl Taq Hifi Buffer, heated to 95 ° C, and then naturally cooled to room temperature;

(8) 上述针对所有基因 sgRNA的产物等量混合; (8) The above-mentioned products for all gene sgRNA are mixed in equal amounts;

(9)上述混合物与 (6) 中构建的载体混合, 加入 mSI限制性内切酶和 T4 连接酶, 37°C 5 min, 16°C 5 min, 重复 10个循环;  (9) The above mixture is mixed with the vector constructed in (6), and mSI restriction endonuclease and T4 ligase are added, and the mixture is repeated at 37 ° C for 5 min, 16 ° C for 5 min, and repeated for 10 cycles;

( 10) 上述产物转化至 Transl-Tl感受态细胞中;  (10) the above product is transformed into Transl-Tl competent cells;

( 11 )从上述转化产物中提取质粒, 构建文库质粒;  (11) extracting a plasmid from the above transformation product to construct a library plasmid;

4. 文库病毒的包装  4. Packaging of library viruses

将 293T细胞以 3 X 106的密度平铺于 4个 10cm直径的细胞培养板中, 使用聚氮 丙啶 (PEI)将文库质粒和其它两种病毒包装质粒 psPAX2和 PMD2.G转入细胞, 70小时后, 收获病毒液; 293T cells were plated at a density of 3×10 6 in four 10 cm diameter cell culture plates, and the library plasmid and the other two viral packaging plasmids psPAX2 and PMD2.G were transferred into the cells using polyethylenimine (PEI). After 70 hours, the virus solution was harvested;

5. 文库细胞的构建  5. Construction of library cells

将筛选出的表达 Cas9的 HeLa细胞以 4 χ 106的密度平铺于 10个 15cm直径的细 胞培养板中, 用上述病毒液按 MOI = 0.05进行感染, 感染 48小时后, 使用流式细 胞仪筛选出表达绿色荧光的细胞; The selected Cas9-expressing HeLa cells were plated at a density of 4 χ 10 6 in 10 15 cm-diameter cell culture plates, infected with the above virus solution at MOI = 0.05, and 48 hours after infection, using a flow cytometer. Screening for cells expressing green fluorescence;

6. 使用白喉毒素进行筛选  6. Screening with diphtheria toxin

将筛选出的细胞以 1 X 106的密度平铺于 10个 10cm的细胞培养板,共三组平行 实验, 在培养液中加入 DT蛋白 7.5 ng/mL, 培养 48小时, 更换新鲜培养液, 重复 此过程三次; 7. 提取基因组 DNA并扩增 The selected cells were plated at a density of 1×10 6 in 10 10 cm cell culture plates, and three groups of parallel experiments were performed. DT protein 7.5 ng/mL was added to the culture medium, cultured for 48 hours, and the fresh culture solution was replaced. Repeat this process three times; 7. Extract genomic DNA and amplify

提取存活的细胞和另外三组未作任何处理的文库细胞的基因组 DN A , 使用 上述引物进行 PCR扩增, 每组作为模板的基因组 DNA总量为 8 μ§, PCR进行 26个 循环, 纯化 PCR产物; The genomic DNA DN A of the surviving cells and the other three groups of untreated library cells were extracted, and the above primers were used for PCR amplification. The total amount of genomic DNA of each group as a template was 8 μ § , PCR was performed for 26 cycles, and PCR was performed. product;

8. 测序并分析  8. Sequencing and analysis

纯化后的 PCR产物使用 HiSeq2500进行测序, 并根据 sgRNA在毒素处理前后 的丰度变化进行排序, 排在第一位的为已知的白喉毒素的受体。  The purified PCR product was sequenced using HiSeq 2500 and sorted according to the abundance change of sgRNA before and after toxin treatment, and the first place was the known receptor for diphtheria toxin.

图 1为本发明 Cas9表达载体(a )和 sgRNA表达载体(b ) 结构示意图。 图 2为本发明利用 CRISPR/Cas系统构建真核基因敲除文库,并用于基因功 能筛选的高通量方法学的实施流程图。  Figure 1 is a schematic view showing the structure of the Cas9 expression vector (a) and the sgRNA expression vector (b) of the present invention. Figure 2 is a flow chart showing the implementation of a high-throughput method for constructing a eukaryotic gene knockout library using the CRISPR/Cas system and for gene function screening.

图 3为本编码方法所涉及的系统在 HEK293T、 HT1080、 HeLa三个细胞系 中均可有效的造成基因组修复错误以达到基因敲除目的。  Fig. 3 shows that the system involved in the coding method can effectively cause genomic repair errors in the three cell lines HEK293T, HT1080 and HeLa to achieve gene knockout.

图 4为应用本发明所述方法分别使用炭疽毒素嵌合毒素和白喉毒素进行筛 选后的候选阳性基因排序结果。  Fig. 4 is a result of sorting candidate positive genes after screening using anthrax toxin chimeric toxin and diphtheria toxin, respectively, using the method of the present invention.

图 5为本发明实施例 1中炭疽毒素嵌合毒素筛选后被最大富集的 ANTXR1 基因对于炭疽毒素嵌合毒素具有较强抗性, 对白喉毒素不具有抗性。  Fig. 5 is a graph showing that the ANTXR1 gene which is most enriched after screening for anthrax toxin chimeric toxin in Example 1 of the present invention has strong resistance to anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.

图 6为本发明实施例 1 中炭疽毒素嵌合毒素筛选后候选基因中 PECR基因 对于炭疽毒素嵌合毒素具有一定的抗性, 对白喉毒素不具有抗性。  Fig. 6 is a diagram showing that the PECR gene in the candidate gene after screening for anthrax toxin chimeric toxin in Example 1 of the present invention has certain resistance to anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.

图 7为本发明实施例 2中白喉毒素筛选后被最大富集的 HBEGF基因对于白 喉毒素具有较强抗性, 对炭疽毒素嵌合毒素不具有抗性。  Fig. 7 shows that the HBEGF gene which is most enriched after screening for diphtheria toxin in Example 2 of the present invention is highly resistant to diphtheria toxin and is not resistant to anthrax toxin chimeric toxin.

虽然, 上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述, 但在本发明基础上, 可以对之作一些修改或改进,这对本领域技术人员而言是显 而易见的。 因此, 在不偏离本发明精神的基础上所做的这些修改或改进, 均属于 本发明要求保护的范围。 工业实用性 本发明提供的利用 CRISPR/Cas9系统构建真核基因敲除文库的方法, 该方 法的最大优点在于: 可将本方法应用于绝大多数真核细胞系中, 不受特定细胞系 的限制。 另外, 进行功能性筛选阳性率高, 背景值低。 大规模的筛选方法极大降 低了成本, 克服了单个制备基因敲除细胞, 所导致的时间和劳动成本高的问题。 参考文献 Although the present invention has been described in detail with reference to the preferred embodiments of the present invention, it will be apparent to those skilled in the art. Therefore, such modifications or improvements made without departing from the spirit of the invention are intended to be within the scope of the invention. INDUSTRIAL APPLICABILITY The present invention provides a method for constructing a eukaryotic gene knockout library using the CRISPR/Cas9 system, and the greatest advantage of the method is that the method can be applied to most eukaryotic cell lines without being affected by a specific cell line. limit. In addition, the functional screening has a high positive rate and a low background value. The large-scale screening method greatly reduces the cost and overcomes the problem of high time and labor cost caused by single preparation of knockout cells. references

Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini,

L.A., et al. (2013). Multiplex Genome Engineering Using CRISPR/Cas Systems. Science. L.A., et al. (2013). Multiplex Genome Engineering Using CRISPR/Cas Systems. Science.

Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, IE., Norville, IE., and Church, G.M. Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, IE., Norville, IE., and Church, G.M.

(2013). RNA-guided human genome engineering via Cas9. Science 339, 823-826. (2013). RNA-guided human genome engineering via Cas9. Science 339, 823-826.

Miller, J.C., Holmes, M.C., Wang, J., Guschin, D.Y., Lee, Y.L., Rupniewski, L, Beausejour, CM., Miller, J.C., Holmes, M.C., Wang, J., Guschin, D.Y., Lee, Y.L., Rupniewski, L, Beausejour, CM.,

Waite, A. J., Wang, N.S., Kim, K.A., et al. (2007). An improved zinc -finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25, 778-785. Waite, A. J., Wang, N.S., Kim, K.A., et al. (2007). An improved zinc -finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25, 778-785.

Miller, J.C., Tan, S., Qiao, G, Barlow, K.A., Wang, J., Xia, D.F Meng, X., Paschon, D.E Leung, E., Hinkley, S丄, et al. (2011). A TALE nuclease architecture for efficient genome editing. Nature biotechnology 29, 143-148.  Miller, JC, Tan, S., Qiao, G, Barlow, KA, Wang, J., Xia, DF Meng, X., Paschon, DE Leung, E., Hinkley, S丄, et al. (2011). A TALE nuclease architecture for efficient genome editing. Nature biotechnology 29, 143-148.

Porteus, M.H., and Baltimore, D. (2003). Chimeric nucleases stimulate gene targeting in human cells. Science 300, 763.  Porteus, M.H., and Baltimore, D. (2003). Chimeric nucleases stimulate gene targeting in human cells. Science 300, 763.

Wood, A.J., Lo, T.W., Zeitler, B., Pickle, C.S., Ralston, E.J., Lee, A.H Amora, R., Miller, J.C., Leung, E., Meng, X., et al (2011). Targeted genome editing across species using ZFNs and TALENs. Science 333, 307.  Wood, AJ, Lo, TW, Zeitler, B., Pickle, CS, Ralston, EJ, Lee, AH Amora, R., Miller, JC, Leung, E., Meng, X., et al (2011). Targeted Particle editing across species using ZFNs and TALENs. Science 333, 307.

Zhang, F., Cong, L., Lodato, S., Kosuri, S., Church, G.M., and Arlotta, P. (2011). Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nature biotechnology 29, 149-153. Zhang, F., Cong, L., Lodato, S., Kosuri, S., Church, GM, and Arlotta, P. (2011). Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. 149-153.

序列表 Sequence table

< 110> 北京大学  < 110> Peking University

< 120> 利用 CRISPR/Cas9系统构建真核基因敲除文库的方法  < 120> Method for constructing eukaryotic gene knockout library using CRISPR/Cas9 system

< 130> KHP143111702 < 130> KHP143111702

< 160> 4 < 160> 4

< 170> Patentln vers ion 3. 3  < 170> Patentln vers ion 3. 3

<210> 1 <210> 1

<211> 8217  <211> 8217

<212> DNA  <212> DNA

<213> 载体 pOCTl- 2A- Cas9- IRES- BSD  <213> Carrier pOCTl-2A- Cas9- IRES- BSD

<400> 1  <400> 1

cgataagctt gggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg 60 cccaacgacc cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata 120 gggactttcc attgacgtca atgggtggag tatttacggt aaactgccca cttggcagta 180 catcaagtgt atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc 240 gcctggcatt atgcccagta catgacctta tgggactttc ctacttggca gtacatctac 300 gtattagtca tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga 360 tagcggtttg actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg 420 ttttggcacc aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg 480 caaatgggcg gtaggcgtgt acggtgggag gtctatataa gcagagctcg tttagtgaac 540 cgtcagatcg cctggagacg ccatccacgc tgttttgacc tccatagaag acaccgacta 600 ctagtttacc ggtgggggcc cccggcgcgc cggtgtacac cctgcagggg tttatgaaca 660 atccgtcaga aaccagtaaa ccatctatgg agagtggaga tggcaacaca ggcacacaaa 720 ccaatggtct ggactttcag aagcagcctg tgcctgtagg aggagcaatc tcaacagccc 780 aggcgcaggc tttccttgga catctccatc aggtccaact cgctggaaca agtttacagg 840 ctgctgctca gtctttaaat gtacagtcta aatctaatga agaatcgggg gattcgcagc 900 agccaagcca gccttcccag cagccttcag tgcaggcagc cattccccag acccagctta 960 tgctagctgg aggacagata actgggctta ctttgacgcc tgcccagcaa cagttactac 1020 tccagcaggc acaggcacag gcacagctgc tggctgctgc agtgcagcag cactccgcca 1080 gccagcagca cagtgctgct ggagccacca tctccgcctc tgctgccacg cccatgacgc 1140 agatccccct gtctcagccc atacagatcg cacaggatct tcaacaactg caacagcttc 1200 aacagcagaa tctcaacctg caacagtttg tgttggtgca tccaaccacc aatttgcagc 1260 cagcgcagtt tatcatctca cagacgcccc agggccagca gggtctcctg caagcgcaaa 1320 atcttctaac gcaactacct cagcaaagcc aagccaacct cctacagtcg cagccaagca 1380 tcaccctcac ctcccagcca gcaaccccaa cacgcacaat agcagcaacc ccaattcaga 1440 cacttccaca gagccagtca acaccaaagc gaattgatac tcccagcttg gaggagccca 1500 gtgaccttga ggagcttgag cagtttgcca agaccttcaa acaaagacga atcaaacttg 1560 gattcactca gggtgatgtt gggctcgcta tggggaaact atatggaaat gacttcagcc 1620 aaactaccat ctctcgattt gaagccttga acctcagctt taagaacatg tgcaagttga 1680 agccactttt agagaagtgg ctaaatgatg cagagaacct ctcatctgat tcgtccctct 1740 ccagcccaag tgccctgaat tctccaggaa ttgagggctt gagccgtagg aggaagaaac 1800 gcaccagcat agagaccaac atccgtgtgg ccttagagaa gagtttcttg gagaatcaaa 1860 agcctacctc ggaagagatc actatgattg ctgatcagct caatatggaa aaagaggtga 1920 ttcgtgtttg gttctgtaac cgccgccaga aagaaaaaag aat caaccca ccaagcagtg 1980 gtgggaccag cagctcacct attaaagcaa ttttccccag cccaacttca ctggtggcga 2040 ccacaccaag ccttgtgact agcagtgcag caactaccct cacagtcagc cctgtcctcc 2100 ctctgaccag tgctgctgtg acgaatcttt cagttacagg cacttcagac accacctcca 2160 acaacacagc aaccgtgatt tccacagcgc ctccagcttc ctcagcagtc acgtccccct 2220 ctctgagtcc ctccccttct gcctcagcct ccacctccga ggcatccagt gccagtgaga 2280 ccagcacaac acagaccacc tccactcctt tgtcctcccc tcttgggacc agccaggtga 2340 tggtgacagc atcaggtttg caaacagcag cagctgctgc ccttcaagga gctgcacagt 2400 tgccagcaaa tgccagtctt gctgccatgg cagctgctgc aggactaaac ccaagcctga 2460 tggcaccctc acagtttgcg gctggaggtg ccttactcag tctgaatcca gggaccctga 2520 gcggtgctct cagcccagct ctaatgagca acagtacact ggcaactatt caagctcttg 2580 cttctggtgg ctctcttcca at aacat cac ttgatgcaac tgggaacctg gtatttgcca 2640 atgcgggagg agcccccaac atcgtgactg cccctctgtt cctgaaccct cagaacctct 2700 ctctgctcac cagcaaccct gttagcttgg tctctgccgc cgcagcatct gcagggaact 2760 ctgcacctgt agccagcctt cacgccacct ccacctctgc tgagtccatc cagaactctc 2820 tcttcacagt ggcctctgcc agcggggctg cgtccaccac caccaccgcc tccaaggcac 2880 agggaagcgg agctactaac ttcagcctgc tgaagcaggc tggagacgtg gaggagaacc 2940 ctggacctat ggccccaaag aagaagcgga aggtcggtat ccacggtgtc ccagcagcca 3000 tggacaagaa gtactccatt gggctcgata tcggcacaaa cagcgtcggc tgggccgtca 3060 ttacggacga gtacaaggtg ccgagcaaaa aattcaaagt tctgggcaat accgatcgcc 3120 acagcataaa gaagaacctc attggcgccc tcctgttcga ctccggggag acggccgaag 3180 ccacgcggct caaaagaaca gcacggcgca gatatacccg cagaaagaat cggatctgct 3240 acctgcagga gatctttagt aatgagatgg ctaaggtgga tgactctttc ttccataggc 3300 tggaggagtc ctttttggtg gaggaggata aaaagcacga gcgccaccca atctttggca 3360 atatcgtgga cgaggtggcg taccatgaaa agtacccaac catatatcat ctgaggaaga 3420 agcttgtaga cagtactgat aaggctgact tgcggttgat ctatctcgcg ctggcgcata 3480 tgatcaaatt tcggggacac ttcctcatcg agggggacct gaacccagac aacagcgatg 3540 tcgacaaact ctttatccaa ctggttcaga cttacaatca gcttttcgaa gagaacccga 3600 tcaacgcatc cggagttgac gccaaagcaa tcctgagcgc taggctgtcc aaatcccggc 3660 ggctcgaaaa cctcatcgca cagctccctg gggagaagaa gaacggcctg tttggtaatc 3720 ttatcgccct gtcactcggg ctgaccccca actttaaatc taacttcgac ctggccgaag 3780 atgccaagct tcaactgagc aaagacacct acgatgatga tctcgacaat ctgctggccc 3840 agatcggcga ccagtacgca gacctttttt tggcggcaaa gaacctgtca gacgccattc 3900 tgctgagtga tattctgcga gtgaacacgg agatcaccaa agctccgctg agcgctagta 3960 tgatcaagcg ctatgatgag caccaccaag acttgacttt gctgaaggcc cttgtcagac 4020 agcaactgcc tgagaagtac aaggaaattt tcttcgatca gtctaaaaat ggctacgccg 4080 gatacattga cggcggagca agccaggagg aat 111 acaa atttattaag cccatcttgg 4140 aaaaaatgga cggcaccgag gagctgctgg taaagcttaa cagagaagat ctgttgcgca 4200 aacagcgcac tttcgacaat ggaagcatcc cccaccagat tcacctgggc gaactgcacg 4260 ctatactcag gcggcaagag gatttctacc cctttttgaa agataacagg gaaaagattg 4320 agaaaatcct cacatttcgg ataccctact atgtaggccc cctcgcccgg ggaaattcca 4380 gattcgcgtg gatgactcgc aaatcagaag agaccatcac tccctggaac ttcgaggaag 4440 tcgtggataa gggggcctct gcccagtcct tcatcgaaag gatgactaac tttgataaaa 4500 atctgcctaa cgaaaaggtg cttcctaaac actctctgct gtacgagtac ttcacagttt 4560 gg gggggg aaaaaaaatt teccccctctcc ctcccccccc cctaactta ctccaa 7200 cgataagctt gggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg 60 cccaacgacc cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata 120 gggactttcc attgacgtca atgggtggag tatttacggt aaactgccca cttggcagta 180 catcaagtgt atcatatgcc aagtacgccc cctattgacg tcaatgacgg 240 gcctggcatt atgcccagta catgacctta tgggactttc ctacttggca gtacatctac 300 gtattagtca tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga 360 tagcggtttg actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg 420 ttttggcacc taaatggccc aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg 480 caaatgggcg gtaggcgtgt acggtgggag gtctatataa gcagagctcg tttagtgaac 540 cgtcagatcg cctggagacg ccatccacgc tgttttgacc tccatagaag acaccgacta 600 ctagtttacc ggtgggggcc cccggcgcgc cggtgtacac cctgcagggg tttatgaaca 660 atccgtcaga aaccagtaaa ccatctatgg agagtggaga tggcaacaca ggcacacaaa 720 ccaatggtct ggactttcag aagcagcctg tgcctgtagg aggagcaatc tcaacagccc 780 aggcgcaggc tttccttgga catctccatc aggtccaact cgctggaaca agtttacagg 840 ctgctgctca gtctttaaat gtacagtcta aatctaatga agaatcgggg gattcgcagc 900 agccaagcca gccttcccag cagccttcag tgcaggcagc cattccccag acccagctta 960 tgctagctgg aggacagata actgggctta ctttgacgcc tgcccagcaa cagttactac 1020 tccagcaggc acaggcacag gcacagctgc tggctgctgc agtgcagcag cactccgcca 1080 gccagcagca cagtgctgct ggagccacca tctccgcctc tgctgccacg cccatgacgc 1140 agatccccct gtctcagccc atacagatcg cacaggatct tcaacaactg caacagcttc 1200 aacagcagaa tctcaacctg caacagtttg tgttggtgca tccaaccacc aatttgcagc 1260 cagcgcagtt tatcatctca cagacgcccc agggccagca gggtctcctg caagcgcaaa 1320 atcttctaac gcaactacct cagcaaagcc aagccaacct cctacagtcg cagccaagca 1380 tcaccctcac ctcccagcca gcaaccccaa cacgcacaat agcagcaacc ccaattcaga 1440 cacttccaca gagccagtca acaccaaagc gaattgatac tcccagcttg gaggagccca 1500 gtgaccttga ggagcttgag cagtttgcca agaccttcaa acaaagacga atcaaacttg 1560 gattcactca gggtgatgtt gggctcgcta tggggaaact atatggaaat gacttcagcc 1620 aaactaccat ctctcgattt gaagccttga acctcagctt taagaacatg tgcaagttga 1680 agccactttt agagaagtgg ctaaatg Atg cagagaacct ctcatctgat tcgtccctct 1740 ccagcccaag tgccctgaat tctccaggaa ttgagggctt gagccgtagg aggaagaaac 1800 gcaccagcat agagaccaac atccgtgtgg ccttagagaa gagtttcttg gagaatcaaa 1860 agcctacctc ggaagagatc actatgattg ctgatcagct caatatggaa aaagaggtga 1920 ttcgtgtttg gttctgtaac cgccgccaga aagaaaaaag aat caaccca ccaagcagtg 1980 gtgggaccag cagctcacct attaaagcaa ttttccccag cccaacttca ctggtggcga 2040 ccacaccaag ccttgtgact agcagtgcag caactaccct cacagtcagc cctgtcctcc 2100 ctctgaccag tgctgctgtg acgaatcttt cagttacagg cacttcagac accacctcca 2160 acaacacagc aaccgtgatt tccacagcgc ctccagcttc ctcagcagtc acgtccccct 2220 ctctgagtcc ctccccttct gcctcagcct ccacctccga ggcatccagt gccagtgaga 2280 ccagcacaac acagaccacc tccactcctt tgtcctcccc tcttgggacc agccaggtga 2340 tggtgacagc atcaggtttg caaacagcag cagctgctgc ccttcaagga gctgcacagt 2400 tgccagcaaa tgccagtctt gctgccatgg cagctgctgc aggactaaac ccaagcctga 2460 tggcaccctc acagtttgcg gctggaggtg ccttactcag tctgaatcca gggaccctga 2520 gcggtgctct cagcccagct ctaatgagca acagtacact ggcaactatt caagctcttg 2580 cttctggtgg ctctcttcca at aacat cac ttgatgcaac tgggaacctg gtatttgcca 2640 atgcgggagg agcccccaac atcgtgactg cccctctgtt cctgaaccct cagaacctct 2700 ctctgctcac cagcaaccct gttagcttgg tctctgccgc cgcagcatct gcagggaact 2760 ctg cacctgt agccagcctt cacgccacct ccacctctgc tgagtccatc cagaactctc 2820 tcttcacagt ggcctctgcc agcggggctg cgtccaccac caccaccgcc tccaaggcac 2880 agggaagcgg agctactaac ttcagcctgc tgaagcaggc tggagacgtg gaggagaacc 2940 ctggacctat ggccccaaag aagaagcgga aggtcggtat ccacggtgtc ccagcagcca 3000 tggacaagaa gtactccatt gggctcgata tcggcacaaa cagcgtcggc tgggccgtca 3060 ttacggacga gtacaaggtg ccgagcaaaa aattcaaagt tctgggcaat accgatcgcc 3120 acagcataaa gaagaacctc attggcgccc tcctgttcga ctccggggag acggccgaag 3180 ccacgcggct caaaagaaca gcacggcgca gatatacccg cagaaagaat cggatctgct 3240 acctgcagga gatctttagt aatgagatgg ctaaggtgga tgactctttc ttccataggc 3300 tggaggagtc ctttttggtg gaggaggata aaaagcacga gcgccaccca atctttggca 3360 atatcgtgga cgaggtggcg taccatgaaa agtacccaac catatatcat ctgaggaaga 3420 agcttgtaga cagtactgat aaggctgact tgcggttgat ctatctcgcg ctggcgcata 3480 tgatcaaatt tcggggacac ttcctcatcg agggggacct gaacccagac aacagcgatg 3540 tcgacaaact ctttatccaa ctggttcaga cttacaatca gcttttcgaa gagaacccga 3600 tcaacgcat c cggagttgac gccaaagcaa tcctgagcgc taggctgtcc aaatcccggc 3660 ggctcgaaaa cctcatcgca cagctccctg gggagaagaa gaacggcctg tttggtaatc 3720 ttatcgccct gtcactcggg ctgaccccca actttaaatc taacttcgac ctggccgaag 3780 atgccaagct tcaactgagc aaagacacct acgatgatga tctcgacaat ctgctggccc 3840 agatcggcga ccagtacgca gacctttttt tggcggcaaa gaacctgtca gacgccattc 3900 tgctgagtga tattctgcga gtgaacacgg agatcaccaa agctccgctg agcgctagta 3960 tgatcaagcg ctatgatgag caccaccaag acttgacttt gctgaaggcc cttgtcagac 4020 agcaactgcc tgagaagtac aaggaaattt tcttcgatca gtctaaaaat ggctacgccg 4080 gatacattga cggcggagca agccaggagg aat 111 acaa atttattaag cccatcttgg 4140 aaaaaatgga cggcaccgag gagctgctgg taaagcttaa cagagaagat ctgttgcgca 4200 aacagcgcac tttcgacaat ggaagcatcc cccaccagat tcacctgggc gaactgcacg 4260 ctatactcag gcggcaagag gatttctacc cctttttgaa agataacagg gaaaagattg 4320 agaaaatcct cacatttcgg ataccctact atgtaggccc cctcgcccgg ggaaattcca 4380 gattcgcgtg gatgactcgc aaatcagaag agaccatcac tccctggaac ttcgaggaag 4440 Tcgtggataa gg Gggcctct gcccagtcct tcatcgaaag gatgactaac tttgataaaa 4500 atctgcctaa cgaaaaggtg cttcctaaac actctctgct gtacgagtac ttcacagttt 4560 Gg gggggg aaaaaaaatt teccccctctcc ctcccccccc cctaactta ctccaa 7200

ggggg ggggggg ggg acctctctcactctaacaactc ctctctac taaaaacttcaacta 7140 Ggggg ggggggg ggg acctctctcactctaacaactc ctctctac taaaaacttcaacta 7140

gggggggggg gggg atccta cccacact attcatcat caattacctctataa acaaaatc 7080 Gggggggggg gggg atccta cccacact attcatcat caattacctctataa acaaaatc 7080

ggg ggg ggggg ctcacctt caatacttcacaccacca taacaaaactacacc tctacaaa 7020 Ggg ggg ggggg ctcacctt caatacttcacaccacca taacaaaactacacc tctacaaa 7020

ggg ggggggggggg ccatcaacacaaa aacattatcc actttttac tctaccaac ttccc 6960 Ggg ggggggggggg ccatcaacacaaa aacattatcc actttttac tctaccaac ttccc 6960

ggg gggggggggg tcctccca cctaacctcataatc tttctctta caataacac aataac 6900 Ggg gggggggggg tcctccca cctaacctcataatc tttctctta caataacac aataac 6900

g ggggggggg ctaccttataatcatc acaaataa caattctcc aaaaata 6840 g ggggggggg ctaccttataatcatc acaaataa caattctcc aaaaata 6840

g gggggggg ggggggg actataaaactcaaa tctcccaa ataatacaaacact ttctaac 6780 g gggggggg ggggggg actataaaactcaaa tctcccaa ataatacaaacact ttctaac 6780

ggggggggggggg aaaataa cactca ctccctcta aatacttaa tttctttat ctccacc 6720 Ggggggggggggg aaaataa cactca ctccctcta aatacttaa tttctttat ctccacc 6720

ggggggggggggg ggggg actctctctt tacttaa aaccca aacaatct cctatccactc 6660 Ggggggggggggg ggggg actctctctt tacttaa aaccca aacaatct cctatccactc 6660

ggg ggggggggg ttctcacaaaatat aaaatca aaaaaacct catcattaa cttcccaat 6600 Ggg ggggggggg ttctcacaaaatat aaaatca aaaaaacct catcattaa cttcccaat 6600

ggg gggggg gggg aaactctcatcaca atcatacatcaactt caaaaaaac cccatcact 6540 Ggg gggggg gggg aaactctcatcaca atcatacatcaactt caaaaaaac cccatcact 6540

gg ggggggggggggggg acattacttttcc aaataa aaaatc aaaactca 6480 Gg ggggggggggggggg acattacttttcc aaataa aaaatc aaaactca 6480

ggggggggggggg caccaaaaa aattac cccaaaaat accatt cattctcct acatcctt 6420 Ggggggggggggg caccaaaaa aattac cccaaaaat accatt cattctcct acatcctt 6420

gggggg gggg gggggg aacca cttctccaaaaatatcc tcccaaaaaacacac aactatc 6360 Gggggg gggg gggggg aacca cttctccaaaaatatcc tcccaaaaaacacac aactatc 6360

ggg ggggggggggggg cacatccaatcct tccatccc ataacat cttaaaaa accaatac 6300 Ggg ggggggggggggg cacatccaatcct tccatccc ataacat cttaaaaa accaatac 6300

ggg ggggggg ggggggggg cacttatca aacaaacaaaacaa aaatcttacaat aatttc 6240 Ggg ggggggg ggggggggg cacttatca aacaaacaaaacaa aaatcttacaat aatttc 6240

gggggggggggggg atattataa ttttttcaa accaatta cactccaa taaatt caacac 6180 Ggggggggggggggg atattataa ttttttcaa accaatta cactccaa taaatt caacac 6180

gg gggg gggggggg tatccaaatctacaaaataca accaccc taatacttc ttttacaca 6120 Gg gggg gggggggg tatccaaatctacaaaataca accaccc taatacttc ttttacaca 6120

ggggg ggggg ggg atcccaact taatctaa ttttttacaactataa attacatttaaaaa 6060 Ggggg ggggg ggg atcccaact taatctaa ttttttacaactataa attacatttaaaaa 6060

g ggggggggggg accaccatccatatcc tacctaat catta cactcactt 6000 g ggggggggggg accaccatccatatcc tacctaat catta cactcactt 6000

gggggggg ggggg acttctc aatttcaa aaactttc attttataataaa 5940 Gggggggg ggggg acttctc aatttcaa aaactttc attttataataaa 5940

Figure imgf000039_0001
ggggg gggggggg ccaataca taaaatac aaactattcaataa attattact ctaatcta 5880
Figure imgf000039_0001
Ggggg gggggggg ccaataca taaaatac aaactattcaataa attattact ctaatcta 5880

gggggggggggg ttttaac acccaatc accaacac tcccaaat tctcattca ccataaca 5820 Gggggggggggg ttttaac acccaatc accaacac tcccaaat tctcattca ccataaca 5820

ggggggggggggggggggg ctaacta acatc cttctat tataaac acttcatc aaaacac 5760 Ggggggggggggggggggg ctaacta acatc cttctat tataaac acttcatc aaaacac 5760

ggg ggggggggg gg attattccactct aacccaaac tatcacaca acaattcataatcta 5700 Ggg ggggggggg gg attattccactct aacccaaac tatcacaca acaattcataatcta 5700

gggggg gggggggg ataaaaata aaaatataactcc cctcaaaa atttcaa aaaataaaa 5640 Gggggg gggggggg ataaaaata aaaatataactcc cctcaaaa atttcaa aaaataaaa 5640

gg ggggggggg tctccccatcttttctc aaaatatt ctattataa taaattt acaaatcc 5580 Gg ggggggggg tctccccatcttttctc aaaatatt ctattataa taaattt acaaatcc 5580

gg gggggggggg ggg acattactatcaaa ctacatca atcctctc cactacactatcata 5520 Gg gggggggggg ggg acattactatcaaa ctacatca atcctctc cactacactatcata 5520

gggggggggggggg ttaaaacac ccacttca aataaac tctacctta ctacctca aacca 5460 Ggggggggggggg ttaaaacac ccacttca aataaac tctacctta ctacctca aacca 5460

ggggggggggggggg gg taaaat taaat ataaaaaac ttccca aatccttaaaacaccca 5400 Ggggggggggggggg gg taaaat taaat ataaaaaac ttccca aatccttaaaacaccca 5400

ggggggggggg gggggggg tcaatc ccaaaac caaactaccc aaaacaaaaacat aaaaa 5340 Ggggggggggg gggggggg tcaatc ccaaaac caaactaccc aaaacaaaaacat aaaaa 5340

ggg ggg ggggggggggg ttaatctataactctcaaataa taaca taaccca aatatctta 5280 Ggg ggg ggggggggggg ttaatctataactctcaaataa taaca taaccca aatatctta 5280

ggg ggggggggggg acacacat cctaatcttcatacc cactatcaa aaaaata ctcaacc 5220 Ggg ggggggggggg acacacat cctaatcttcatacc cactatcaa aaaaata ctcaacc 5220

ggggggggggggg gg ctctcacctt taaaac atccaaaa cacaatttc tccaacatcttc 5160  Ggggggggggggg gg ctctcacctt taaaac atccaaaa cacaatttc tccaacatcttc 5160

ggggg gg ggggg attttcttaatccata tttccaaccaacttcatcattatc catatact 5100  Ggggg gg ggggg attttcttaatccata tttccaaccaacttcatcattatc catatact 5100

gggggggg ggg gggggggcttcaa aaaactatc aatatccaacaacaataaa acaatcct 5040 Gggggggg ggg gggggggcttcaa aaaactatc aatatccaacaacaataaa acaatcct 5040

gggggggggg ggggggg atctcttca cacaaatc ataaacac tcaaac ccatatacaatc 4980  Gggggggggg ggggggg atctcttca cacaaatc ataaacac tcaaac ccatatacaatc 4980

ggg ggggggggggg tcacccttactttttaaataaa tattaaa accttaaa acttacctc 4920 Ggg ggggggggggg tcacccttactttttaaataaa tattaaa accttaaa acttacctc 4920

g ggg gggggggggg gg tt aaaacaaacttcctacaata aaacaa cattcttaacatttcc 4860  g ggg gggggggggg gg tt aaaacaaacttcctacaata aaacaa cattcttaacatttcc 4860

gggggg ggggggggggcataatccttc aaccatccc taacta tcacatctc ctaaaatca 4800 Gggggg ggggggggggcataatccttc aaccatccc taacta tcacatctc ctaaaatca 4800

gggggggg gg taaacact caaaaaac aattaat tttcactctttaaatca 4740 Ggggggggg gg taaacact caaaaaac aattaat tttcactctttaaatca 4740

gggg gggggg gggggg ctaacaaaaaact atctacc tcctcttcaaacaacc aaattacc 4680 ggggggggg ggg gg ataacact caccaatc aaatactca caaaataaaaccacattcctt 4620 ccgcttggaa taaggccggt gtgcgtttgt ctatatgtga ttttccacca tattgccgtc 7260 Gggg gggggg gggggg ctaacaaaaaact atctacc tcctcttcaaacaacc aaattacc 4680 ggggggggg ggg gg ataacact caccaatc aaatactca caaaataaaaccacattcctt 4620 Ccgcttggaa taaggccggt gtgcgtttgt ctatatgtga ttttccacca tattgccgtc 7260

ttttggcaat gtgagggccc ggaaacctgg ccctgtcttc ttgacgagca ttcctagggg 7320 Ttttggcaat gtgagggccc ggaaacctgg ccctgtcttc ttgacgagca ttcctagggg 7320

tctttcccct ctcgccaaag gaatgcaagg tctgttgaat gtcgtgaagg aagcagttcc 7380 Tctttcccct ctcgccaaag gaatgcaagg tctgttgaat gtcgtgaagg aagcagttcc 7380

tctggaagct tcttgaagac aaacaacgtc tgtagcgacc ctttgcaggc agcggaaccc 7440 Tctggaagct tcttgaagac aaacaacgtc tgtagcgacc ctttgcaggc agcggaaccc 7440

cccacctggc gacaggtgcc tctgcggcca aaagccacgt gtataagata cacctgcaaa 7500 Cccacctggc gacaggtgcc tctgcggcca aaagccacgt gtataagata cacctgcaaa 7500

ggcggcacaa ccccagtgcc acgttgtgag ttggatagtt gtggaaagag tcaaatggct 7560 Ggcggcacaa ccccagtgcc acgttgtgag ttggatagtt gtggaaagag tcaaatggct 7560

ctcctcaagc gtattcaaca aggggctgaa ggatgcccag aaggtacccc attgtatggg 7620 Ctcctcaagc gtattcaaca aggggctgaa ggatgcccag aaggtacccc attgtatggg 7620

atctgatctg gggcctcggt gcacatgctt tacatgtgtt tagtcgaggt taaaaaaacg 7680 Atctgatctg gggcctcggt gcacatgctt tacatgtgtt tagtcgaggt taaaaaaacg 7680

tctaggcccc ccgaaccacg gggacgtggt tttcctttga aaaacacgat gataagctag 7740 Tctaggcccc ccgaaccacg gggacgtggt tttcctttga aaaacacgat gataagctag 7740

ctcgagcacg tgttgacaat taatcatcgg catagtatat cggcatagta taatacgaca 7800 Ctcgagcacg tgttgacaat taatcatcgg catagtatat cggcatagta taatacgaca 7800

aggtgaggaa ctaaaccatg gccaagcctt tgtctcaaga agaatccacc ctcattgaaa 7860 Aggtgaggaa ctaaaccatg gccaagcctt tgtctcaaga agaatccacc ctcattgaaa 7860

gagcaacggc ~ acaat caac agcatcccca tctctgaaga ctacagcgtc gccagcgcag 7920 Gagcaacggc ~ acaat caac agcatcccca tctctgaaga ctacagcgtc gccagcgcag 7920

ctctctctag cgacggccgc atcttcactg gtgtcaatgt atatcatttt actgggggac 7980 Ctctctctag cgacggccgc atcttcactg gtgtcaatgt atatcatttt actgggggac 7980

cttgtgcaga actcgtggtg ctgggcactg ctgctgctgc ggcagctggc aacctgactt 8040 Cttgtgcaga actcgtggtg ctgggcactg ctgctgctgc ggcagctggc aacctgactt 8040

gtatcgtcgc gatcggaaat gagaacaggg gcatcttgag cccctgcgga cggtgccgac 8100 Gtatcgtcgc gatcggaaat gagaacaggg gcatcttgag cccctgcgga cggtgccgac 8100

aggtgcttct cgatctgcat cctgggatca aagccatagt gaaggacagt gatggacagc 8160

Figure imgf000040_0001
Figure imgf000040_0002
Aggtgcttct cgatctgcat cctgggatca aagccatagt gaaggacagt gatggacagc 8160
Figure imgf000040_0001
Figure imgf000040_0002

<210> 3  <210> 3

<211> 20  <211> 20

<212> DNA  <212> DNA

<213> 人工序列  <213> Artificial sequence

<400> 3  <400> 3

aatacggtta tccacgcggc 20 Aatacggtta tccacgcggc 20

<210> 4  <210> 4

<211> 66  <211> 66

<212> DNA  <212> DNA

Claims

权 利 要 求 书 KHP143111702 Claim KHP143111702 1. 一种利用 CRISPR/Cas9系统构建真核基因敲除文库的方法, 其特征在于, 包括以下步骤: A method for constructing a eukaryotic gene knockout library using a CRISPR/Cas9 system, comprising the steps of: 1 )构建稳定表达 OCT1蛋白和 Cas9蛋白的真核细胞系: 将编码蛋白 OCT1和 Cas9的 DNA序列 通过柔性 Linker连接 , 然后 克隆至慢病毒载体 pOCTl-2A-Cas9-IRES-BSD上; 用构建好的载体转染真核宿主细胞; 筛选稳定表 达 OCT1蛋白和 Cas9蛋白的真核细胞系; 其中, 载体 pOCTl-2A-Cas9-IRES-BSD 的序列如 SEQ ID No.1所示;  1) Construction of a eukaryotic cell line stably expressing OCT1 protein and Cas9 protein: The DNA sequences encoding the proteins OCT1 and Cas9 were ligated through a flexible Linker, and then cloned into the lentiviral vector pOCTl-2A-Cas9-IRES-BSD; The vector is transfected into a eukaryotic host cell; a eukaryotic cell line stably expressing the OCT1 protein and the Cas9 protein is screened; wherein the sequence of the vector pOCT1-2A-Cas9-IRES-BSD is as shown in SEQ ID No. 1; 2 ) sgRNA质粒文库的构建:  2) Construction of sgRNA plasmid library: i. 根据 sgRNA作用位点的 DNA序列 5' -G-Nx-NGG-3' , 其中 19 < x < 22, 设 计并合成针对上述作用位点的 sgRNA单体,针对同一个 sgRNA作用位点设计两个 sgRNA单体,其序列分别为正向单体: 5' -ACCG-Nx-3' ,反向单体: 5' -AAAC-N' χ-3' , 其中 N' X为 Nx的反向互补序列, N和 N' 表示碱基 、 T、 G或 C;  i. According to the DNA sequence of sgRNA action site 5'-G-Nx-NGG-3', where 19 < x < 22, design and synthesize sgRNA monomer targeting the above-mentioned site of action, designing for the same sgRNA action site Two sgRNA monomers, the sequence of which is forward monomer: 5'-ACCG-Nx-3', reverse monomer: 5'-AAAC-N' χ-3', where N' X is the inverse of Nx To a complementary sequence, N and N' represent a base, T, G or C; ii. 将上述合成的针对同一个 sgRNA作用位点的两个 sgRNA单体退火形成具 有粘性末端的双链 DNA, 并将针对所有基因合成的 sgRNA单体经退火形成的双 链 DNA等量混合;  Ii. annealing the two sgRNA monomers synthesized above for the same sgRNA action site to form double-stranded DNA having sticky ends, and mixing the double-stranded DNA formed by annealing the sgRNA monomers synthesized for all genes in equal amounts; iii. 将人 U6启动子连接 ccdB序列以及序列 5' -G-Nx-NGG-3 ' 之后, 连入 PLL3.7载体中替换原载体上的 U6启动子, 将构建好的载体与 ii中得到的混合物混 合, 加入 fismfil限制性内切酶和 T4连接酶, 37°C 5 min, 16°C 5 min, 重复 10个 循环;  Iii. After the human U6 promoter is ligated to the ccdB sequence and the sequence 5'-G-Nx-NGG-3', it is ligated into the PLL3.7 vector to replace the U6 promoter on the original vector, and the constructed vector and ii are obtained. Mix the mixture, add fisfil restriction endonuclease and T4 ligase, 37 ° C for 5 min, 16 ° C for 5 min, repeat 10 cycles; iv. 将上述产物转化至 Transl-Tl感受态细胞中, 提取质粒, 即构建得到 sgRNA质粒文库;  Iv. transforming the above product into Transl-Tl competent cells, extracting the plasmid, and constructing the sgRNA plasmid library; 3 )将上述质粒文库中的质粒与质粒 psPAX2和 PMD2.G共转染至 HEK293T细 胞中, 培养细胞, 收获病毒液;  3) co-transfecting the plasmid in the above plasmid library with the plasmids psPAX2 and PMD2.G into HEK293T cells, culturing the cells, and harvesting the virus solution; 4 )用收获的病毒液按 0.01≤MOI≤0.3接种步骤 1 ) 中构建得到的真核细胞系, 细胞经培养后, 使用流式细胞仪分选带有绿色荧光的细胞, 即获得真核基因敲除 的细胞文库。 4) Inoculate the eukaryotic cell line constructed in step 1) with the harvested virus solution at 0.01 ≤ MOI ≤ 0.3. After the cells are cultured, the cells with green fluorescence are sorted by flow cytometry to obtain the eukaryotic gene. Knockout cell library. 2. 根据权利要求 1所述的方法, 其特征在于, 步骤 1 ) 中所述真核宿主细胞 包括但不限于 HEK293T、 HT1080、 HeLa细胞。 2. The method according to claim 1, wherein the eukaryotic host cell in step 1) comprises, but is not limited to, HEK293T, HT1080, HeLa cells. 3. 根据权利要求 1所述的方法, 其特征在于, 步骤 1 ) 中所述柔性 Linker序 列为 p2 A: 5 '-GGAAGCGGAGCTACTAACTTC AGCCTGCTGAAGC AGGCTGGA GACGTGGAGGAGAACCCTGGACCT-3 '。  The method according to claim 1, wherein the flexible Linker sequence in step 1) is p2 A: 5 '-GGAAGCGGAGCTACTAACTTC AGCCTGCTGAAGC AGGCTGGA GACGTGGAGGAGAACCCTGGACCT-3 '. 4. 根据权利要求 1-3任一项所述方法构建的真核基因敲除细胞文库。  4. A library of eukaryotic knockout cells constructed according to the method of any of claims 1-3. 5. 一种研究基因功能的方法, 其特征在于, 基于权利要求 4所述的细胞文 库, 提取细胞的基因组 DNA, 设计引物, PCR扩增含有 sgRNA序列的 DNA片段, 利用深度测序技术对扩增产物进行测序, 分析测序结果, 从而确定 sgRNA所对应 基因的功能。  A method for studying gene function, characterized in that, based on the cell library of claim 4, extracting genomic DNA of a cell, designing a primer, PCR-amplifying a DNA fragment containing the sgRNA sequence, and amplifying by using a deep sequencing technique The product is sequenced and the sequencing results are analyzed to determine the function of the gene corresponding to the sgRNA. 6. 根据权利要求 5所述的方法, 其特征在于, 所述引物序列为正向引物: 5' -TATCTTGTGGAAAGGACGAAACACC-3' , 反向引物: 5' -AATACGGTTATCC ACGCGGC-3'。  6. The method according to claim 5, wherein the primer sequence is a forward primer: 5'-TATCTTGTGGAAAGGACGAAACACC-3', and the reverse primer: 5'-AATACGGTTATCC ACGCGGC-3'.
PCT/CN2014/078586 2013-12-31 2014-05-28 Method for constructing eukaryotic gene knockout library by using crispr/cas9 system Ceased WO2015100929A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310751755.0A CN103668472B (en) 2013-12-31 2013-12-31 Method for constructing eukaryon gene knockout library by using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system
CN201310751755.0 2013-12-31

Publications (1)

Publication Number Publication Date
WO2015100929A1 true WO2015100929A1 (en) 2015-07-09

Family

ID=50307222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/078586 Ceased WO2015100929A1 (en) 2013-12-31 2014-05-28 Method for constructing eukaryotic gene knockout library by using crispr/cas9 system

Country Status (2)

Country Link
CN (1) CN103668472B (en)
WO (1) WO2015100929A1 (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
WO2018020050A1 (en) * 2016-07-29 2018-02-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Targeted in situ protein diversification by site directed dna cleavage and repair
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
WO2018236079A1 (en) * 2017-06-19 2018-12-27 서울대학교병원 Liver fibrosis induction vector and method for manufacturing animal model using the same
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US10227581B2 (en) 2013-08-22 2019-03-12 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US10669539B2 (en) 2016-10-06 2020-06-02 Pioneer Biolabs, Llc Methods and compositions for generating CRISPR guide RNA libraries
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3816292A4 (en) * 2018-07-04 2022-01-05 Guangdong Sanjie Forage Biotechnology Co., Ltd PROCESS FOR OBTAINING MULTI-LEAF ALFALFAMATERIAL USING ARTIFICIAL SITUATED MSPALM1 MUTANT
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434776A1 (en) 2012-12-12 2019-01-30 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
CN110872583A (en) 2012-12-12 2020-03-10 布罗德研究所有限公司 Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
EP3011033B1 (en) 2013-06-17 2020-02-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
CN113425857B (en) 2013-06-17 2025-05-16 布罗德研究所有限公司 Delivery and use of CRISPR-Cas systems, vectors and compositions for liver targeting and treatment
CN105793425B (en) 2013-06-17 2021-10-26 布罗德研究所有限公司 Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using viral components
EP3011029B1 (en) 2013-06-17 2019-12-11 The Broad Institute, Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
EP4245853A3 (en) 2013-06-17 2023-10-18 The Broad Institute, Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
EP4219699A1 (en) 2013-12-12 2023-08-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
CN111206032B (en) 2013-12-12 2024-07-19 布罗德研究所有限公司 Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for genome editing
MX2016007325A (en) 2013-12-12 2017-07-19 Broad Inst Inc Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders.
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
SG10201804975PA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
JP6793547B2 (en) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド Optimization Function Systems, methods and compositions for sequence manipulation with the CRISPR-Cas system
CN103668472B (en) * 2013-12-31 2014-12-24 北京大学 Method for constructing eukaryon gene knockout library by using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system
CN103911376B (en) * 2014-04-03 2017-02-15 黄行许 CRISPR-Cas9 targeted knockout hepatitis b virus cccDNA and specific sgRNA thereof
CN103981216B (en) * 2014-05-23 2016-06-22 安徽省农业科学院水稻研究所 A kind of key plasmid vector and application
CN104178512B (en) * 2014-05-30 2017-07-21 广州辉园苑医药科技有限公司 A kind of androgen receptor gene knocks out kit
CA3176503A1 (en) * 2014-07-21 2016-01-28 Illumina, Inc Polynucleotide enrichment using crispr-cas systems
WO2016058171A1 (en) * 2014-10-17 2016-04-21 Shanghai Sidansai Biotechnology Co.,Ltd Method for directional cloning
CN104450774A (en) * 2014-12-04 2015-03-25 中国农业科学院作物科学研究所 Construction of soybean CRISPR/Cas9 system and application of soybean CRISPR/Cas9 system in soybean gene modification
EP3230451B1 (en) 2014-12-12 2021-04-07 The Broad Institute, Inc. Protected guide rnas (pgrnas)
CN104560864B (en) * 2014-12-22 2017-08-11 中国科学院微生物研究所 Utilize the 293T cell lines of the knockout IFN β genes of CRISPR Cas9 system constructings
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
SG10201906070XA (en) 2014-12-31 2019-08-27 Synthetic Genomics Inc Compositions and methods for high efficiency in vivo genome editing
WO2016187904A1 (en) * 2015-05-22 2016-12-01 深圳市第二人民医院 Method for pig cmah gene specific knockout by means of crispr-cas9 and sgrna for specially targeting cmah gene
CN104894071A (en) * 2015-06-08 2015-09-09 东华大学 Method for carrying out gene edition on GT1-7 cells
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
JP7107683B2 (en) 2015-06-18 2022-07-27 ザ・ブロード・インスティテュート・インコーポレイテッド CRISPR enzyme mutations that reduce off-target effects
CN106399361A (en) * 2015-07-30 2017-02-15 聂凌云 Method for screening mitochondria genome editing tool targeting target sequence
CN105567692B (en) * 2016-02-26 2018-08-14 浙江大学 A kind of sgRNA of selectively targeted QKI genes and its application
CN107513538A (en) * 2016-06-17 2017-12-26 北京大学 Gene knockout method
CN107784200B (en) * 2016-08-26 2020-11-06 深圳华大生命科学研究院 Method and device for screening novel CRISPR-Cas system
CN106399377A (en) * 2016-09-07 2017-02-15 同济大学 Method for screening drug target genes based on CRISPR/Cas9 high-throughput technology
CN106637421B (en) * 2016-10-28 2019-12-27 博雅缉因(北京)生物科技有限公司 Construction of double sgRNA library and method for applying double sgRNA library to high-throughput functional screening research
US20230183884A1 (en) * 2016-11-30 2023-06-15 China Agricultural University A method for crispr library screening
CN106755026A (en) * 2016-12-18 2017-05-31 吉林大学 The foundation of the structure and enamel hypocalcification model of sgRNA expression vectors
CN106978399A (en) * 2017-02-16 2017-07-25 华中农业大学 The mouse macrophage and construction method of nlrp3 gene knockouts
CN106939317A (en) * 2017-03-24 2017-07-11 华南农业大学 It is a kind of to improve the method that plant resists the ability of RNA virus
CN108728476A (en) * 2017-04-14 2018-11-02 复旦大学 A method of generating diversity antibody library using CRISPR systems
CN107099850B (en) * 2017-06-19 2018-05-04 东北农业大学 A kind of method that CRISPR/Cas9 genomic knockouts library is built by digestion genome
CN107236763A (en) * 2017-06-26 2017-10-10 中南民族大学 A kind of method for building Knockout cells system based on flow cytometry
CN109207515A (en) 2017-07-03 2019-01-15 华中农业大学 A method of design and building pig full-length genome CRISPR/Cas9 knock out library
WO2019024081A1 (en) 2017-08-04 2019-02-07 北京大学 Tale rvd specifically recognizing dna base modified by methylation and application thereof
US11624077B2 (en) 2017-08-08 2023-04-11 Peking University Gene knockout method
CN109385421A (en) * 2017-08-08 2019-02-26 北京大学 Gene knockout method
CN108148866B (en) * 2018-01-19 2020-09-01 中国人民解放军第三0二医院 HCBP6 gene knockout cell line and construction method thereof
CN110373430B (en) * 2018-04-13 2021-02-19 青岛清原化合物有限公司 Random mutation gene editing system and application thereof
JP7641233B2 (en) * 2019-04-12 2025-03-06 アストラゼネカ・アクチエボラーグ Compositions and methods for improved gene editing
CN113122578A (en) * 2019-12-30 2021-07-16 博雅缉因(北京)生物科技有限公司 Electric shock transformation method for efficiently constructing cell library
CN111549052A (en) * 2020-05-07 2020-08-18 西南大学 Eukaryotic organism CRISPR/Cas whole genome editing vector library and construction method
CN117587013B (en) * 2023-11-27 2024-06-14 湖南师范大学 Construction method of zebra fish model for vascular dysplasia
CN119193789B (en) * 2024-09-30 2025-06-20 北京大学 A method combining spatial transcriptome and CRISPR screening in an unbiased manner and its application in gene function verification

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013141680A1 (en) * 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
CN103668472A (en) * 2013-12-31 2014-03-26 北京大学 Method for constructing eukaryon gene knockout library by using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013141680A1 (en) * 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
CN103668472A (en) * 2013-12-31 2014-03-26 北京大学 Method for constructing eukaryon gene knockout library by using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHO, S.W. ET AL.: "Heritable Gene Knockout in Caenorhabditis elegans by Direct Injection of Cas9-sgRNA Ribonucleoproteins", GENETICS, vol. 195, 30 November 2013 (2013-11-30), pages 1177 - 1180 *
MIAO, J. ET AL.: "Targeted mutagenesis in rice using CRISPR-Cas system", CELL RES, vol. 23, no. 10, 3 September 2013 (2013-09-03), pages 1233 - 1236 *

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US12006520B2 (en) 2011-07-22 2024-06-11 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10954548B2 (en) 2013-08-09 2021-03-23 President And Fellows Of Harvard College Nuclease profiling system
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US11920181B2 (en) 2013-08-09 2024-03-05 President And Fellows Of Harvard College Nuclease profiling system
US10227581B2 (en) 2013-08-22 2019-03-12 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9999671B2 (en) 2013-09-06 2018-06-19 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US10682410B2 (en) 2013-09-06 2020-06-16 President And Fellows Of Harvard College Delivery system for functional nucleases
US10912833B2 (en) 2013-09-06 2021-02-09 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US11299755B2 (en) 2013-09-06 2022-04-12 President And Fellows Of Harvard College Switchable CAS9 nucleases and uses thereof
US12473573B2 (en) 2013-09-06 2025-11-18 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US10190137B2 (en) 2013-11-07 2019-01-29 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US10640788B2 (en) 2013-11-07 2020-05-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAs
US11390887B2 (en) 2013-11-07 2022-07-19 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
US12215365B2 (en) 2013-12-12 2025-02-04 President And Fellows Of Harvard College Cas variants for gene editing
US11124782B2 (en) 2013-12-12 2021-09-21 President And Fellows Of Harvard College Cas variants for gene editing
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
US10704062B2 (en) 2014-07-30 2020-07-07 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US12398406B2 (en) 2014-07-30 2025-08-26 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11578343B2 (en) 2014-07-30 2023-02-14 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11214780B2 (en) 2015-10-23 2022-01-04 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
US12344869B2 (en) 2015-10-23 2025-07-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
WO2017158153A1 (en) 2016-03-17 2017-09-21 Imba - Institut Für Molekulare Biotechnologie Gmbh Conditional crispr sgrna expression
WO2018020050A1 (en) * 2016-07-29 2018-02-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Targeted in situ protein diversification by site directed dna cleavage and repair
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11702651B2 (en) 2016-08-03 2023-07-18 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11999947B2 (en) 2016-08-03 2024-06-04 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10947530B2 (en) 2016-08-03 2021-03-16 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US12084663B2 (en) 2016-08-24 2024-09-10 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US10669539B2 (en) 2016-10-06 2020-06-02 Pioneer Biolabs, Llc Methods and compositions for generating CRISPR guide RNA libraries
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11820969B2 (en) 2016-12-23 2023-11-21 President And Fellows Of Harvard College Editing of CCR2 receptor gene to protect against HIV infection
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US12435331B2 (en) 2017-03-10 2025-10-07 President And Fellows Of Harvard College Cytosine to guanine base editor
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2018236079A1 (en) * 2017-06-19 2018-12-27 서울대학교병원 Liver fibrosis induction vector and method for manufacturing animal model using the same
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US12359218B2 (en) 2017-07-28 2025-07-15 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11932884B2 (en) 2017-08-30 2024-03-19 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3816292A4 (en) * 2018-07-04 2022-01-05 Guangdong Sanjie Forage Biotechnology Co., Ltd PROCESS FOR OBTAINING MULTI-LEAF ALFALFAMATERIAL USING ARTIFICIAL SITUATED MSPALM1 MUTANT
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
US12281303B2 (en) 2019-03-19 2025-04-22 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11643652B2 (en) 2019-03-19 2023-05-09 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11795452B2 (en) 2019-03-19 2023-10-24 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US12031126B2 (en) 2020-05-08 2024-07-09 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence

Also Published As

Publication number Publication date
CN103668472B (en) 2014-12-24
CN103668472A (en) 2014-03-26

Similar Documents

Publication Publication Date Title
WO2015100929A1 (en) Method for constructing eukaryotic gene knockout library by using crispr/cas9 system
CN114269919B (en) Targeted RNA editing with engineered RNA using endogenous ADAR
CN110295149B (en) A mutant strain type 3 duck hepatitis A virus CH-P60-117C strain and construction method
KR20230045612A (en) KRAB fusion inhibitors and methods and compositions for inhibiting gene expression
CN117015605A (en) Targeted RNA editing using engineered RNAs by utilizing endogenous ADAR
Guan et al. RNA targeting with CRISPR-Cas13a facilitates bacteriophage genome engineering
CN109055375B (en) Method for activating gene expression by CRISPR (clustered regularly interspaced short palindromic repeats) auxiliary trans-enhancer and application of method
CN114350615B (en) STAT2 gene deletion cell strain and preparation method and application thereof
CN113549656A (en) Lentiviral vector expression system for polygene transformation
CN108949794B (en) A kind of TALE expression vector and its rapid construction method and application
CN101260408B (en) Construction method and application of two-color fluorescence report carrier
CN109321571A (en) A method of utilizing CRISPR/Cas9 preparation and reorganization porcine pseudorabies virus
CN114369619A (en) Reporter vector and vector system for gene knockout and application
CN112029736A (en) Recombinant pseudorabies live vaccine for preventing African swine fever and preparation method thereof
CN109371167A (en) Genetic elements and the application of frameshift mutation are generated for detecting CRISPR/Cas9 gene editing system cutting gene
CN114395017B (en) Preparation method and application of SARS-CoV-2 virus-like particle
CN110295180B (en) Type 3 duck hepatitis A virus mutant gene ISA-A117C-C4334A and construction method thereof
CN110684781B (en) A kind of type 3 duck hepatitis A virus mutant gene ISA-A117C-T1142A and construction method
CN114395579B (en) Gene I and gene III Japanese encephalitis virus infectious clone and construction method and application thereof
CN101186925B (en) Universal high-efficiency eukaryotic expression vector p3I-GFPN and anti-mastitis transgene vector constructed by using the vector
CN103131709B (en) Ribonucleic acid (RNA) interference fragment of zinc finger-x (zfx) gene and application of RNA interference fragment in mouse sex control
CN110283835B (en) Type 3 duck hepatitis A virus mutant gene ISA-T1142A-C4334A and construction method
CN113652406B (en) Recombinant virus strain for infectious laryngotracheitis of chickens and application thereof
CN110484546B (en) Type-3 duck hepatitis A virus mutant gene ISA-C4334A and construction method
CN104195153A (en) Bicistronic co-expression gene transfer bodyand preparation method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14876418

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205N DATED 12-10-2016

122 Ep: pct application non-entry in european phase

Ref document number: 14876418

Country of ref document: EP

Kind code of ref document: A1